3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF2) dependent diseases

By developing compounds with IKZF2 degradation activity, the problem of T effector cell activation in existing anti-CTLA4 treatment methods is solved, and Treg-specific degradation in tumors is achieved, which enhances immune response and provides a safer and more effective cancer Treatment pathway.

CN112334194BActive Publication Date: 2024-12-06NOVARTIS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980041638.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-07-10
Filing Date
2019-07-08
Publication Date
2024-12-06
Estimated Expiration
2039-07-08

AI Technical Summary

Technical Problem

Existing anti-CTLA4 treatments often cause systemic activation of T effector cells when targeting tumors, resulting in excessive toxicity and limited therapeutic utility, and lack of compounds that can specifically target Treg without activate T effector cells.

Method used

Developing compounds with IKZF2 degradation activity, especially 3-(5-amino-1-oxoisoindoline-2-yl)piperidine-2,6-dione compounds, with selective degradation of IKZF2, IKZF1, IKZF3 , IKZF4 and/or IKZF5, preferably at or below 50 μM levels, are used to reduce IKZF2 levels in Treg in tumors, thereby enhancing the immune response.

Benefits of technology

By reducing the IKZF2 level in Treg in tumors, enhancing the immune system's ability to attack tumors, providing a more tolerant and less toxic treatment method, avoiding systemic activation of T-effector cells and improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112334194B_ABST
    Figure CN112334194B_ABST
Patent Text Reader

Abstract

The present disclosure provides a compound having formula (I'): (I') or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R a , R b , R x , R i , R2, X2 and q are as defined herein; methods of manufacture and use thereof in treating disorders or diseases associated with reduced levels of IKZF2 protein. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 695,922, filed on July 10, 2018, the entire contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] The present disclosure relates to 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds and compositions, and their use for treating IKAROS family zinc finger 2 (IKZF2)-dependent diseases or disorders (or where reduction of IKZF2 or IKZF4 protein levels can alleviate the disease or disorder). Background Art

[0004] IKAROS family zinc finger 2 (IKZF2) (also known as Helios) is one of five members of the Ikaros family of transcription factors found in mammals. IKZF2 contains four zinc finger domains near the N-terminus, which are involved in DNA binding, and two zinc finger domains at the C-terminus, which are involved in protein dimerization. IKZF2 shares approximately 50% identity with the Ikaros family members Ikaros (IKZF1), Aiolos (IKZF3), and Eos (IKZF4), with the highest homology (80%+ identity) in the zinc finger region. These four Ikaros family transcription factors bind to the same consensus DNA site and can heterodimerize with each other when co-expressed in cells. The fifth Ikaros family protein, Pegasus (IKZF5), shares only 25% identity with IKZF2, binds to a different DNA site than the other Ikaros family members, and is less likely to heterodimerize with other Ikaros family proteins. IKZF2, IKZF1, and IKZF3 are primarily expressed in hematopoietic cells, whereas IKZF4 and IKZF5 are expressed in a variety of tissues (John, LB, et al. (2011), Mol. Immunol. 48:1272-1278; Perdomo, J., et al. (2000), J. Biol. Chem. 275:38347-38354).

[0005] It is believed that IKZF2 plays an important role in the function and stability of regulatory T cells (Treg). IKZF2 is highly expressed at the mRNA and protein levels by regulatory T cell populations. It has been shown that knocking down IKZF2 by siRNA leads to the downregulation of FoxP3 and damages the ability of isolated human CD4+CD25+Treg to block T cell activation in vitro. In addition, it has been shown that overexpression of IKZF2 in isolated mouse Treg increases the expression of Treg-related markers such as CD103 and GITR, and cells overexpressing IKZF2 show increased suppression of responding T cells. It has also been found that IKZF2 binds to the promoter of FoxP3 (a defining transcription factor of the regulatory T cell lineage) and affects FoxP3 expression.

[0006] It has been shown that knockout of IKZF2 within FoxP3-expressing Tregs in mice causes activated Tregs to lose their suppressive properties, express T-effector cytokines, and assume T-effector functions. IKZF2 knockout mutant mice develop autoimmune disease at 6-8 months of age, with increased numbers of activated CD4 and CD8 T cells, follicular helper T cells, and germinal center B cells. This observed effect is thought to be cell-intrinsic, as Rag2- / - mice given bone marrow from IKZF2 knockout mice, but not from IKZF2+ / + mice, develop autoimmune disease. Direct evidence that IKZF2 influences regulatory T cell function has been shown in analyses of mice in which IKZF2 is deleted exclusively in FoxP3-expressing cells (FoxP3-YFP-CreHeliosfl / fl). The results showed that the mice also develop autoimmune disease with similar features to those observed in whole-animal IKZF2 knockout. In addition, pathway analysis of the CHIP-seq experiment also showed that IKZF2 affects the expression of genes in the STAT5 / IL-2Rα pathway in regulatory T cells. This effect of IKZF2 loss was more pronounced after immune challenge (viral infection or injection with sheep blood), and it was noted that after immune stimulation, IKZF2 negative regulatory T cells began to take on the characteristics of effector T cells. (Getnet, D. et al., Mol. Immunol. [Molecular Immunology] (2010), 47: 1595-1600; Bin Dhuban, K. et al., (2015), J. Immunol. [Journal of Immunology] 194: 3687-96; Kim, HJ. et al., (2015), Science [Science] 350: 334-339; Nakawaga, H. et al., (2016) PNAS [Proceedings of the National Academy of Sciences of the United States of America], 113: 6248-6253)

[0007] Overexpression of Ikaros isoforms lacking a DNA binding region has been shown to be associated with a variety of human hematological malignancies. Recently, mutations in the IKZF2 gene that cause abnormal splicing variants have been identified in adult T-cell leukemia and low hypodiploid acute lymphoblastic leukemia. It has been proposed that these isoforms capable of dimerization have a dominant negative effect on the Ikaros family transcription factors that cause lymphoma development. IKZF2 knockout mutants that survive to adulthood do not develop lymphoma, which supports this hypothesis (Asanuma, S. et al., (2013), Cancer Sci. [Cancer Science] 104: 1097-1106; Zhang, Z. et al., (2007), Blood [Blood] 109: 2190-2197; Kataoka, D. et al., (2015), Nature Genetics [Natural Genetics] 47: 1304-1315).

[0008] At present, anti-CTLA4 antibodies are used in the clinic to target Treg in tumors. However, targeting CTLA4 often causes systemic activation of T effector cells, resulting in excessive toxicity and limiting therapeutic utility. Up to 3 / 4 of patients treated with a combination of anti-PD1 and anti-CTLA4 reported grade 3 or higher adverse events (National Cancer Institute, Division of Cancer Treatment & diagnosis, Common Terminology for Adverse Events (CTCAE), https: / / ctep.cancer.gov / protocolDevelopment / electronic_applications / ctc.htm). Therefore, there is a strong need to provide compounds that target Treg in tumors without causing systemic activation of T effector cells.

[0009] IKZF2-specific degraders have the potential to focus enhanced immune responses to areas within or near tumors, providing potentially more tolerable and less toxic therapeutics for the treatment of cancer. Summary of the Invention

[0010] The compounds disclosed herein have uses as therapeutic agents, particularly for cancer and related diseases. In one aspect, the compounds disclosed herein have IKZF2 degradation activity, preferably having activity equal to or less than 50 μM, and more preferably having activity equal to or less than 10 μM. In another aspect, the compounds disclosed herein have degradation activity against IKZF2, and this degradation activity is selective for one or more of IKZF1, IKZF3, IKZF4, and / or IKZF5. In another aspect, the compounds disclosed herein have degradation activity against both IKZF2 and IKZF4. The compounds disclosed herein are useful in treating cancer and other diseases in which such degradation activity is beneficial to patients. For example, while not intending to be bound by any theory, the inventors believe that reducing the level of IKZF2 in Tregs in tumors can enable the patient's immune system to more effectively attack the disease. In summary, the present disclosure provides novel IKZF2 degraders for the treatment of cancer and other diseases.

[0011] The first aspect of the present disclosure relates to compounds having formula (I')

[0012]

[0013] in:

[0014] X1 and X2 are each independently H, (C1-C4) alkyl, (C1-C6) alkoxy, (C1-C4) haloalkyl,

[0015] (C1-C6)haloalkoxy, (C3-C7)cycloalkyl, halogen, CN, -OH, or -NH2;

[0016] R x is H or D;

[0017] Each R a and R b are independently H or D, or R a and R b Together with the atoms to which they are attached, they form =(O);

[0018] R1 is

[0019] R2 is H, (C1-C6)alkyl, (C1-C6)haloalkyl, or (C3-C6)cycloalkyl; or

[0020] R2 and R7 together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycloalkyl ring;

[0021] each R3, at each occurrence, is independently (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, CN, -OH, or -NH2; or

[0022] Two R3 together with the carbon atom to which they are attached form a (C3-C7)cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S; or when two R3 are on adjacent carbon atoms, together form a phenyl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N and S; or

[0023] R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, the heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, the heterocycloalkyl ring optionally substituted with one to four substituents, each of the one to four substituents being independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, and -NH2;

[0024] each R4 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, -OH, or -NH2;

[0025] R5 is -OR6 or -NR7R 7’ ;

[0026] R6 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -C(O)(C1-C6) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S;

[0027] R7 and R 7’ are each independently H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C7)cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 replace; or

[0028] R7 and R 7’ together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to four R9; or

[0029] R2 and R7 together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycloalkyl ring; or

[0030] R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, the heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, the heterocycloalkyl ring optionally substituted with one to four substituents, each of the one to four substituents being independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, and -NH2;

[0031] Each R8 is -C(O)OH, (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one to four R 10 replace;

[0032] Each R9, at each occurrence, is independently (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, -OH, CN, -NR 12 R 13 , or -NH2, wherein the alkoxy is optionally substituted by one to three substituents, the one to three substituents being independently selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S; or

[0033] Two R9 together with the atoms to which they are attached form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N and S;

[0034] Each R 10 is independently at each occurrence (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, -OH, CN, or -NH2; or

[0035] Two R's10 Together with the atoms to which they are attached, they form a (C4-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S, the cycloalkyl or the heterocycloalkyl ring being optionally substituted with one to four substituents each independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2;

[0036] Each R 11 is independently at each occurrence (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, -OH, CN, or -NH2;

[0037] R 12 and R 13 Each is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S;

[0038] m and m1 are each independently 0, 1 or 2;

[0039] n1 is 0, 1, 2, or 3;

[0040] n2 and n3 are each independently 1 or 2; and

[0041] Each s and n is independently 1, 2, or 3, wherein s+n≤4;

[0042] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0043] In one embodiment, the present disclosure relates to a compound having formula (I'), which has the structure of formula (I):

[0044]

[0045] in:

[0046] R x is H or D;

[0047] R1 is

[0048] R2 is H, (C1-C6)alkyl, (C1-C6)haloalkyl, or (C3-C6)cycloalkyl; or

[0049] R2 and R7 together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycloalkyl ring;

[0050] each R3, at each occurrence, is independently (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, CN, -OH, or -NH2; or

[0051] Two R3 together with the carbon atom to which they are attached form a (C3-C7)cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S; or when two R3 are on adjacent carbon atoms, together form a phenyl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N and S; or

[0052] R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, the heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, the heterocycloalkyl ring optionally substituted with one to four substituents, each of the one to four substituents being independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, and -NH2;

[0053] each R4 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, -OH, or -NH2;

[0054] R5 is -OR6 or -NR7R 7’ ;

[0055] R6 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -C(O)(C1-C6) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S;

[0056] R7 and R 7’ are each independently H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C7)cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8; or

[0057] R7 and R 7’ together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to four R9; or

[0058] R2 and R7 together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycloalkyl ring; or

[0059] R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, the heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, the heterocycloalkyl ring optionally substituted with one to four substituents, each of the one to four substituents being independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, and -NH2;

[0060] Each R8 is (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one to four R 10 replace;

[0061] each R9, at each occurrence, is independently (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2; or

[0062] Two R9 together with the atoms to which they are attached form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N and S;

[0063] Each R 10 is independently at each occurrence (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2; or

[0064] Two R's 10 Together with the atoms to which they are attached, they form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S, the cycloalkyl or the heterocycloalkyl ring being optionally substituted with one to four substituents each independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2;

[0065] m and m1 are each independently 0, 1 or 2;

[0066] n1 is 0, 1, 2, or 3; and

[0067] Each s and n is independently 1, 2, or 3, wherein s+n≤4;

[0068] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0069] In one aspect of the present disclosure, the hydrogen in the compound of formula (I') or formula (I) is present in its normal isotopic abundance. In a preferred aspect of the present disclosure, the hydrogen isotopically enriched in deuterium (D), and in a particularly preferred aspect of the present invention, position R x The hydrogen enrichment D is discussed in more detail below with respect to isotopes and isotopic enrichment.

[0070] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is useful in treating IKZF2-dependent diseases or disorders. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.

[0071] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient, for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder. The pharmaceutical composition is useful in treating an IKZF2-dependent disease or disorder. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.

[0072] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is useful in treating a disease or disorder affected by a decrease in IKZF2 protein levels. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.

[0073] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient, for use in treating a disease or disorder affected by reduced IKZF2 protein levels, wherein the reduced IKZF2 protein levels treat the disease or disorder. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.

[0074] In another aspect, the present disclosure relates to a method for degrading IKZF2, comprising administering to a patient in need thereof a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0075] Another aspect of the present disclosure relates to a method of regulating IKZF2 protein levels. The method comprises administering to a patient in need thereof a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0076] In another aspect, the present disclosure relates to a method for reducing IKZF2 protein levels. The method comprises administering to a patient in need thereof a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0077] In another aspect, the present disclosure relates to a method of reducing IKZF2 protein levels. The method comprises administering to a patient in need thereof a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0078] Another aspect of the present disclosure relates to a method for reducing cell proliferation, comprising administering a compound of Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof to a patient in need thereof, and reducing IKZF2 protein levels.

[0079] In another aspect, the present disclosure relates to a method for reducing IKZF2 protein levels. The method comprises administering to a patient in need thereof a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0080] On the other hand, present disclosure relates to a method for treating cancer. The method includes administering a compound of formula (I') or formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof to a patient in need. In one embodiment, the cancer is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumor, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and soft tissue sarcoma, the soft tissue sarcoma is selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In another embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia and gastrointestinal stromal tumor (GIST). In another embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC) and microsatellite stable colorectal cancer (mssCRC). In another embodiment, the cancer is a cancer of immune response defect or an immunogenic cancer.

[0081] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient, for use in treating an IKZF2-dependent disease or disorder.

[0082] In another aspect, the present disclosure relates to the use of a pharmaceutical composition in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder, the pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

[0083] Another aspect of the present disclosure relates to a method for treating an IKZF2-dependent disease or disorder, comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.

[0084] In another aspect, the present disclosure relates to a method for treating an IKZF2-dependent disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0085] Another aspect of the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder.

[0086] In another aspect, the disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder.

[0087] Another aspect of the present disclosure relates to a method for treating a disease or disorder affected by modulation of IKZF2 protein levels, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0088] In another aspect, the present disclosure relates to a method for treating a disease or disorder affected by a decrease in IKZF2 protein levels, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0089] Another aspect of the present disclosure relates to a method for treating a disease or disorder affected by decreased IKZF2 protein levels, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0090] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by modulation of IKZF2 protein levels.

[0091] Another aspect of the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by decreased IKZF2 protein levels.

[0092] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by a decrease in IKZF2 protein levels.

[0093] In another aspect, the disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by modulation of IKZF2 protein levels.

[0094] Another aspect of the disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by decreased IKZF2 protein levels.

[0095] Another aspect of the disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by reduced IKZF2 protein levels.

[0096] In another aspect, the present disclosure relates to a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the cancer is an immune response-deficient cancer or an immunogenic cancer.

[0097] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease or disorder associated with modulation of IKZF2 protein levels. In one embodiment, the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0098] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for treating a disease or disorder associated with modulation of IKZF2 protein levels. In one embodiment, the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0099] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease or disorder associated with a decrease in IKZF2 protein levels. In one embodiment, the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0100] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for treating a disease or disorder associated with a decrease in IKZF2 protein levels. In one embodiment, the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0101] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease or disorder associated with a decrease in IKZF2 protein levels. In one embodiment, the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0102] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for treating a disease or disorder associated with a decrease in IKZF2 protein levels. In one embodiment, the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0103] Another aspect of the present disclosure relates to a method of treating cancer, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the cancer is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0104] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating cancer, wherein the cancer is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0105] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating cancer, wherein the cancer is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0106] In another aspect, the present disclosure relates to a method of treating a disease or disorder affected by modulation of IKZF2 protein levels, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0107] Another aspect of the present disclosure relates to a method of treating a disease or disorder affected by decreased levels of IKZF2 protein, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0108] In another aspect, the present disclosure relates to a method of treating a disease or disorder affected by decreased levels of IKZF2 protein, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0109] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by modulation of IKZF2 protein levels, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0110] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by decreased levels of IKZF2 protein, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0111] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by decreased levels of IKZF2 protein, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0112] In another aspect, the disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by modulation of IKZF2 levels, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0113] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by decreased levels of IKZF2 protein, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0114] In another aspect, the disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by a decrease in IKZF2 protein levels, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and a soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing's sarcoma. In one embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC).

[0115] In another aspect, the present disclosure relates to a method of treating a disease or disorder affected by modulation of IKZF2 protein levels, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0116] Another aspect of the present disclosure relates to a method of treating a disease or disorder affected by decreased levels of IKZF2 protein, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0117] In another aspect, the present disclosure relates to a method of treating a disease or disorder affected by a decrease in IKZF2 protein levels, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0118] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by modulation of IKZF2 protein levels, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0119] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by decreased levels of IKZF2 protein, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0120] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by a decrease in IKZF2 protein levels, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0121] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by modulation of IKZF2 protein levels, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0122] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by decreased levels of IKZF2 protein, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0123] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder affected by a decrease in IKZF2 protein levels, wherein the disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0124] In another aspect, the present disclosure relates to a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the cancer is an immune response-deficient cancer or an immunogenic cancer.

[0125] Another aspect of the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating immune response-deficient cancer or immunogenic cancer.

[0126] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating immune response-deficient cancer or immunogenic cancer.

[0127] Another aspect of the present disclosure relates to a method for treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0128] In another aspect, the present disclosure relates to a method of treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0129] Another aspect of the present disclosure relates to a method of treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0130] Another aspect of the present disclosure relates to a method for treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0131] In another aspect, the present disclosure relates to a method for treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0132] Another aspect of the present disclosure relates to a method for treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0133] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0134] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the IKZF2-dependent disease or disorder.

[0135] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0136] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0137] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0138] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0139] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in treating an IKZF2-dependent disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the IKZF2-dependent disease or disorder.

[0140] Another aspect of the present disclosure relates to the use of a pharmaceutical composition for treating an IKZF2-dependent disease or disorder by reducing the level of IKZF2 protein, the pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in the level of IKZF2 protein treats the IKZF2-dependent disease or disorder.

[0141] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0142] Another aspect of the present disclosure relates to the use of a pharmaceutical composition for treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, the pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0143] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0144] Another aspect of the present disclosure relates to the use of a pharmaceutical composition for treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, the pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0145] Another aspect of the present disclosure relates to a method of treating a disease or disorder by reducing the level of IKZF2 protein, the method comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in the level of IKZF2 protein treats the disease or disorder.

[0146] In another aspect, the disclosure relates to a method of treating a disease or disorder by reducing the level of IKZF2 protein, the method comprising the step of administering to a subject in need thereof a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in the level of IKZF2 protein treats the disease or disorder.

[0147] Another aspect of the present disclosure relates to a method for treating a disease or disorder by modulating IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein modulation of IKZF2 protein levels treats the disease or disorder.

[0148] In another aspect, the present disclosure relates to a method of treating a disease or disorder by modulating IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein modulation of IKZF2 protein levels treats the disease or disorder.

[0149] Another aspect of the present disclosure relates to a method of treating a disease or disorder by reducing IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein reducing IKZF2 protein levels treats the disease or disorder.

[0150] In another aspect, the disclosure relates to a method of treating a disease or disorder by reducing IKZF2 protein levels, the method comprising the step of administering to a subject in need thereof a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein reducing IKZF2 protein levels treats the disease or disorder.

[0151] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the IKZF2-dependent disease or disorder.

[0152] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0153] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0154] In another aspect, the present disclosure relates to a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0155] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein reducing IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0156] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein reducing IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0157] Another aspect of the present disclosure relates to a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the disease or disorder.

[0158] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the disease or disorder.

[0159] Another aspect of the present disclosure relates to a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the disease or disorder.

[0160] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the disease or disorder.

[0161] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by reducing IKZF2 protein levels, wherein reducing IKZF2 protein levels treats the disease or disorder.

[0162] In another aspect, the disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by reducing IKZF2 protein levels, wherein reducing IKZF2 protein levels treats the disease or disorder.

[0163] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the IKZF2-dependent disease or disorder.

[0164] In another aspect, the present disclosure relates to the use of a pharmaceutical composition in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder by reducing the level of IKZF2 protein, the pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in the level of IKZF2 protein treats the IKZF2-dependent disease or disorder.

[0165] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0166] In another aspect, the present disclosure relates to the use of a pharmaceutical composition in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder by modulating IKZF2 protein levels, the pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein modulation of IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0167] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, wherein reducing IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0168] In another aspect, the present disclosure relates to the use of a pharmaceutical composition in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder by reducing IKZF2 protein levels, the pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein reducing IKZF2 protein levels treats the IKZF2-dependent disease or disorder.

[0169] Another aspect of the present disclosure relates to the use of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the disease or disorder.

[0170] In another aspect, the disclosure relates to the use of a pharmaceutical composition in the manufacture of a medicament for treating a disease or disorder by reducing the level of IKZF2 protein, the pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein the reduction in the level of IKZF2 protein treats the disease or disorder.

[0171] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the disease or disorder.

[0172] In another aspect, the present disclosure relates to the use of a pharmaceutical composition in the manufacture of a medicament for treating a disease or disorder by modulating IKZF2 protein levels, the pharmaceutical composition comprising a therapeutically effective amount of a compound having Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein modulation of IKZF2 protein levels treats the disease or disorder.

[0173] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder by reducing IKZF2 protein levels, wherein reducing IKZF2 protein levels treats the disease or disorder.

[0174] In another aspect, the disclosure relates to the use of a pharmaceutical composition in the manufacture of a medicament for treating a disease or disorder by reducing IKZF2 protein levels, the pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein reducing IKZF2 protein levels treats the disease or disorder.

[0175] Another aspect of the present disclosure relates to a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the disease or disorder.

[0176] In another aspect, the disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the disease or disorder.

[0177] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder by reducing IKZF2 protein levels, wherein reducing IKZF2 protein levels treats the disease or disorder.

[0178] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in treating a disease or disorder by reducing the level of IKZF2 protein, wherein the reduction in the level of IKZF2 protein treats the disease or disorder.

[0179] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in treating a disease or disorder by modulating IKZF2 protein levels, wherein modulation of IKZF2 protein levels treats the disease or disorder.

[0180] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in treating a disease or disorder by reducing IKZF2 protein levels, wherein the reduction in IKZF2 protein levels treats the disease or disorder.

[0181] In another aspect of the present disclosure, the compound according to the present disclosure is formulated into a pharmaceutical composition comprising an effective amount, preferably a pharmaceutically effective amount, of the compound according to the present disclosure or a salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable excipient or carrier.

[0182] Another aspect of the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating an IKZF2-dependent disease or disorder.

[0183] In another aspect, the disclosure relates to a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease associated with regulating IKZF2 protein levels.

[0184] Another aspect of the disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in treating a disease associated with modulation of IKZF2 protein levels.

[0185] In some embodiments of the methods disclosed herein, administration of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, is performed orally, parenterally, subcutaneously, by injection, or by infusion.

[0186] The present disclosure provides degraders of IKZF2 that are therapeutic agents in treating diseases such as cancer and metastasis, in treating diseases affected by modulation of IKZF2 protein levels, and in treating IKZF2-dependent diseases or disorders.

[0187] In one embodiment, the disease or disorder that can be treated by the compounds of the present disclosure is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer and soft tissue sarcoma, the soft tissue sarcoma is selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma and Ewing's sarcoma. In another embodiment, the disease or disorder that can be treated by the compounds of the present disclosure is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia and gastrointestinal stromal tumor (GIST). In another embodiment, the disease or disorder that can be treated by the compounds of the present disclosure is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), and microsatellite stable colorectal cancer (mssCRC). In another embodiment, the IKZF2-dependent disease or disorder is an immune response-deficient cancer or an immunogenic cancer.

[0188] The present disclosure provides agents with novel mechanisms of action for IKZF2 proteins in the treatment of different types of diseases, including cancer and metastasis, in the treatment of diseases affected by modulation of IKZF2 protein levels, and in the treatment of IKZF2-dependent diseases or disorders. Ultimately, the present disclosure provides the medical community with novel pharmacological strategies for treating diseases and disorders associated with the IKZF2 protein. DETAILED DESCRIPTION

[0189] The present disclosure relates to compounds and compositions capable of regulating IKZF2 protein levels. The present disclosure features methods for treating, preventing, or alleviating a disease or disorder, wherein IKZF2 is activated by administering a therapeutically effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to a patient in need thereof. The methods of the present disclosure can be used to treat various IKZF2-dependent diseases and disorders by regulating IKZF2 protein levels. Regulating IKZF2 protein levels through degradation provides a novel approach for treating, preventing, or alleviating diseases (including but not limited to cancer and metathesis) and other IKZF2-dependent diseases or disorders.

[0190] In one aspect, the compounds disclosed herein have uses as therapeutic agents, particularly for cancer and related diseases. In one aspect, the compounds disclosed herein have IKZF2 degradation activity, preferably having activity equal to or less than 50 μM, and more preferably having activity equal to or less than 10 μM. In another aspect, the compounds disclosed herein have degradation activity against IKZF2, and this degradation activity is selective for one or more of IKZF1, IKZF3, IKZF4, and / or IKZF5. In another aspect, the compounds disclosed herein have degradation activity against both IKZF2 and IKZF4. The compounds disclosed herein have usefulness in treating cancer and other diseases in which such degradation activity is beneficial to patients. For example, while not intending to be bound by any theory, the inventors believe that reducing the level of IKZF2 in Tregs in tumors can enable the patient's immune system to more effectively attack the disease. In summary, the present disclosure provides novel IKZF2 degraders for the treatment of cancer and other diseases.

[0191] In a first aspect of the present disclosure, compounds having formula (I') are described:

[0192]

[0193] or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, and tautomer thereof, wherein R a 、R b 、R x , R1, R2, X1, and X2 are as described above.

[0194] The details of the present disclosure are set forth in the specification sheet attached below. Although methods and materials similar or equivalent to those described herein can be used for the practice or testing of the present disclosure, illustrative methods and materials are now described. According to the specification sheet and according to the claims, other features, objects and advantages of the present disclosure will be clear. In this specification sheet and the appended claims, the singular form also includes the plural form, unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present disclosure belongs. All patents and public documents cited in this specification sheet are incorporated by reference in their entirety.

[0195] Definitions of terms and conventions used

[0196] Terms that are not explicitly defined herein should be understood to have the meanings that would be derived by those skilled in the art based on this disclosure and the context. However, unless otherwise indicated, the following terms as used in this specification and the appended claims have the indicated meanings and adhere to the following conventions.

[0197] A. Chemical Nomenclature, Terminology, and Conventions

[0198] In the groups, radicals or moieties defined below, the number of carbon atoms is usually indicated before the radical, e.g. (C1-C 10 ) alkyl means an alkyl group with 1 to 10 carbon atoms. Generally speaking, for a group comprising two or more subgroups, the last group mentioned is the group connection point, for example, "alkylaryl" means a monovalent group of the formula alkyl-aryl-, and "arylalkyl" means a monovalent group of the formula aryl-alkyl-. In addition, the term "a" is used to represent a monovalent group and wherein a divalent group is suitable, it should be understood to represent the corresponding divalent group, and vice versa. Unless otherwise stated, the conventional definition of the term reference and the atomic valence of conventional stable atoms are assumed and embodied in all formulas and groups. The article "a / an" refers to one / kind or more than one / kind (e.g., at least one / kind) of the grammatical object of the article. For example, "an element" means one element or more than one element.

[0199] Unless otherwise indicated, the term "and / or" means "and" or "or".

[0200] The term "optionally substituted" means that a given chemical moiety (e.g., an alkyl group) can (but is not required to) be bonded to other substituents (e.g., heteroatoms). For example, an optionally substituted alkyl group can be a fully saturated alkyl chain (e.g., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents other than hydrogen. For example, it can be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein at any position along the chain. Thus, the term "optionally substituted" means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any other functional groups. Suitable substituents for optional substitution of the groups include, but are not limited to, halogen, oxo, -OH, -CN, -COOH, -CH2CN, -O-(C1-C6)alkyl, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, -O-(C2-C6)alkenyl, -O-(C2-C6)alkynyl, (C2-C6)alkenyl, (C2-C6)alkynyl, -OH, -OP(O)(OH )2, -OC(O)(C1-C6)alkyl, -C(O)(C1-C6)alkyl, -OC(O)O(C1-C6)alkyl, -NH2, -NH((C1-C6)alkyl), -N((C1-C6)alkyl)2, -NHC(O)(C1-C6)alkyl, -C(O)NH(C1-C6)alkyl, -S(O)2(C1-C6)alkyl, -S(O)NH(C1-C6)alkyl, and S(O)N((C1-C6)alkyl)2. The substituents themselves may be optionally substituted. As used herein, "optionally substituted" also refers to substituted or unsubstituted, the meaning of which is described below.

[0201] The term "substituted" means that the specified group or moiety bears one or more suitable substituents, wherein the substituents may be attached to the specified group or moiety at one or more positions. For example, an aryl group substituted with a cycloalkyl group may indicate that the cycloalkyl group is attached to an atom of the aryl group by a bond or by being fused to the aryl group and sharing two or more common atoms.

[0202] The term "unsubstituted" means that the specified group has no substituents.

[0203] Unless otherwise specifically defined, "aryl" means a cyclic aromatic hydrocarbon group having 1 to 3 aromatic rings (including monocyclic or bicyclic groups), such as phenyl, biphenyl, or naphthyl. When containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group are optionally connected at a single point (e.g., biphenyl) or fused (e.g., naphthyl). The aryl group is optionally substituted with one or more substituents at any point of attachment, for example, 1 to 5 substituents. Exemplary substituents include, but are not limited to, -H, -halogen, -CN, -O-(C-C)alkyl, (C-C)alkyl, -O-(C-C)alkenyl, -O-(C-C)alkynyl, (C-C)alkenyl, (C-C)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(C-C)alkyl, -C(O)(C-C)alkyl, -OC(O)O(C-C)alkyl, -NH2, -NH((C-C)alkyl), -N((C-C)alkyl)2, -S(O)2-(C-C)alkyl, -S(O)NH(C-C)alkyl, and S(O)N((C-C)alkyl)2. The substituents themselves are optionally substituted. In addition, when containing two fused rings, the aryl group optionally has an unsaturated or partially saturated ring fused to the fully saturated ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthyl, tetrahydrobenzoannulyl, etc.

[0204] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic aromatic group or polycyclic aromatic group of 5 to 24 ring atoms, which contains one or more ring heteroatoms selected from N, O, or S, the remaining ring atoms being C. Heteroaryl as defined herein also means a bicyclic heteroaromatic group, wherein the heteroatoms are selected from N, O, or S. Aromatic groups are optionally substituted independently with one or more substituents as described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thien-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1, 2-b]pyrazolyl, fluoro[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl , indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzooxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzooxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrahydroquinolinyl, dihydrobenzothiazine ...thiazine, dihydrobenzothiazine, dihydrobenzothiazine, dihydrobenzothiazine, dihydrobenzothiazine, dihydrobenzothiazine, dihydro Azo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydropyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1Δ 2-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, fluoro[3,2-c]pyridinyl, fluoro[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzoxazolyl, benzisoxazolyl, fluoro[2,3-b]pyridinyl, benzophenylthio, 1,5-naphthyridinyl, fluoro[3,2-b]pyridine, [1,2,4]triazolo[l,5-a]pyridinyl, benzo[1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4] Triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. In addition, when containing two fused rings, the aryl groups defined herein may have an unsaturated or partially saturated ring fused to a fully saturated ring. Exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzooxanyl.

[0205] Halogen or "halo" means fluorine, chlorine, bromine, or iodine.

[0206] "Alkyl" means a straight or branched chain saturated hydrocarbon containing 1 to 12 carbon atoms. Examples of (C1-C6)alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.

[0207] "Alkoxy" means a straight or branched chain saturated hydrocarbon containing 1 to 12 carbon atoms, which contains a terminal "O" in the chain, such as -O(alkyl). Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, or pentoxy groups.

[0208] "Alkenyl" means a straight or branched unsaturated hydrocarbon containing 2-12 carbon atoms. An "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, isobutenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted and can be straight or branched.

[0209] "Alkynyl" means a straight or branched unsaturated hydrocarbon containing 2-12 carbon atoms. An "alkynyl" group contains at least one triple bond in the chain. Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, isobutynyl, pentynyl, or hexynyl. Alkynyl groups can be unsubstituted or substituted.

[0210] "Cycloalkyl" or "carbocyclyl" means a monocyclic or polycyclic saturated carbocyclic ring containing 3-18 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl and derivatives thereof. (C3-C8)cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms. Cycloalkyl groups can be fused (e.g., decalin) or bridged (e.g., norbornadiene).

[0211] "Heterocyclyl" or "heterocycloalkyl" means a saturated or partially saturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen or sulfur (O, N or S), and wherein there are no shared delocalized n electrons (aromaticity) between the ring carbons or heteroatoms. The heterocycloalkyl ring structure may be substituted with one or more substituents. The substituents themselves may be optionally substituted. Examples of heterocyclyl rings include, but are not limited to, oxetane, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxolinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, aza Oxalic acid Base, diazepine alkyl, tropanyl, oxazolidinyl, 1,4-dioxanyl, dihydrofuranyl, 1,3-dioxolanyl, imidazolidinyl, imidazolinyl, dithiolanyl, and homotropanyl.

[0212] "Haloalkyl" means an alkyl group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, and the like.

[0213] "Haloalkoxy" means an alkoxy group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, and the like.

[0214] "Cyano" refers to a substituent having a nitrogen atom and a carbon atom connected by a triple bond, for example, C≡N.

[0215] "Amino" means a substituent containing at least one nitrogen atom (eg, -NH2).

[0216] B. Salt, Prodrug, Derivative, and Solvate Terms and Conventions

[0217] "Prodrug" or "prodrug derivative" means a covalently bonded derivative or carrier of a parent compound or active drug substance that undergoes at least some biotransformation before exhibiting one or more of its pharmacological effects. Generally speaking, such prodrugs have metabolically cleavable groups and are rapidly converted in vivo to produce the parent compound, for example, by hydrolysis in the blood, and generally include ester and amide analogs of the parent compound. Prodrugs are formulated with the goal of improving chemical stability, improving patient acceptance and compliance, improving bioavailability, extending duration of action, improving organ selectivity, improving formulations (e.g., increased water solubility) and / or reducing side effects (e.g., toxicity). Generally speaking, the prodrug itself has weak biological activity or no biological activity and is stable under normal conditions.Prodrugs can be readily prepared from the parent compound using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, in particular Chapter 5: "Design and Applications of Prodrugs"; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, KB Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academic Press, 1996. [Academic Press], 1985, in particular, pages 309-396; Burger's Medicinal Chemistry and Drug Discovery, 5th ed., M. Wolff (ed.), John Wiley & Sons, 1995, in particular, volume 1 and pages 172-178 and 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975; Bioreversible Carriers in Drug Design, E. B. Roche (ed.), Elsevier, 1987, each of which is incorporated herein by reference in its entirety.

[0218] As used herein, "pharmaceutically acceptable prodrug" means a prodrug of the compounds of the present disclosure that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio, and, where possible, effective for its intended use as well as in zwitterionic form.

[0219] "Salt" means an ionic form of a parent compound or the product of the reaction between a parent compound and a suitable acid or base to prepare an acid salt or basic salt of the parent compound. Salts of the compounds of the present disclosure can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. Generally, salts are prepared by reacting a free basic or acidic parent compound with a stoichiometric amount or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

[0220] "Pharmaceutically acceptable salts" means salts of the compounds of the present disclosure that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit / risk ratio, are generally water-soluble or oil-soluble or dispersible, and are effective for their intended use. The term includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. Since the compounds of the present disclosure are useful in both free base form and salt form, in practice, using the salt form is equivalent to using the base form. A list of suitable salts is found, for example, in SM Birge et al., J. Pharm. Sci., 1977, 66, pp. 1-19, which is hereby incorporated by reference in its entirety.

[0221] "Pharmaceutically acceptable acid addition salts" means those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable and which are prepared with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, etc.) and organic acids (e.g., acetic acid, trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2-acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic ... The present invention also includes but is not limited to amino acid, glycolic acid, glycerophosphate, hemisulfuric acid, heptanoic acid, hexanoic acid, formic acid, fumaric acid, 2-hydroxyethanesulfonic acid (hydroxyethylsulfonic acid), lactic acid, maleic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, pamoic acid, pectic acid, phenylacetic acid, 3-phenylpropionic acid, picric acid, pivalic acid, propionic acid, pyruvic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, p-aminobenzenesulfonic acid, tartaric acid, p-toluenesulfonic acid, undecanoic acid, etc.

[0222] "Pharmaceutically acceptable base addition salts" means salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable and which are formed with inorganic bases (e.g., ammonia or hydroxides, carbonates, or ammonium bicarbonate) or metal cations (e.g., sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, etc.). Particularly preferred are ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amine compounds, substituted amines (including naturally occurring substituted amines), cyclic amines, and basic ion exchange resins such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, thiazolinone ... Preferred organic non-toxic bases include phenanthene, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium compounds, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine, 1-diphenylhydroxymethylamine, N,N'-dibenzylethylenediamine, polyamine resins, etc. Particularly preferred organic non-toxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

[0223] "Solvate" means a complex of variable stoichiometry formed by a solute (e.g., a compound of Formula (I') or Formula (I)) and a solvent (e.g., water, ethanol, or acetic acid). This physical association may involve varying degrees of ionic and covalent bonds, including hydrogen bonds. In some cases, the solvate is capable of separation (e.g., when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid). Generally, such solvents selected for the purposes of this disclosure do not interfere with the biological activity of the solute. Solvates encompass both solution-phase and separable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.

[0224] "Hydrate" means a solvate wherein one or more of the solvent molecules is water.

[0225] The compounds of the present disclosure, as discussed below, include their free bases or acids, their salts, solvates, and prodrugs, and may include oxidized sulfur atoms or quaternized nitrogen atoms in their structures (even if not explicitly stated or shown), particularly their pharmaceutically acceptable forms. Such forms (particularly pharmaceutically acceptable forms) are intended to be included in the appended claims.

[0226] C. Isomer Terminology and Conventions

[0227] "Isomers" means compounds that have the same number and kind of atoms, and therefore the same molecular weight, but differ with respect to the arrangement or configuration of the atoms in space. The term includes stereoisomers and geometric isomers.

[0228] "Stereoisomer" or "optical isomer" means a stable isomer having at least one chiral atom or restricted rotation resulting in a vertical asymmetric plane (e.g., some biphenyls, allenes, and spirocyclic compounds) and that can rotate plane-polarized light. Because asymmetric centers and other chemical structures are present in the compounds of the present disclosure that can cause stereoisomerism, the present disclosure contemplates stereoisomers and mixtures thereof. The compounds of the present disclosure and their salts include asymmetric carbon atoms and therefore can exist as single stereoisomers, racemates, and mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as racemic mixtures. However, if desired, such compounds can be prepared or separated into stereoisomers, i.e., as individual enantiomers or diastereomers, or as mixtures enriched in stereoisomers. As discussed in more detail below, individual stereoisomers of a compound are prepared by synthesis from optically active starting materials containing the desired chiral centre, or by preparing a mixture of enantiomeric products followed by separation or resolution (e.g., conversion to a mixture of diastereomers followed by separation or recrystallisation, chromatographic techniques, use of a chiral resolving agent, or direct separation of the enantiomers on a chiral chromatographic column). Starting compounds of specific stereochemistry are either commercially available or prepared by the methods described below and resolved by techniques well known in the art.

[0229] "Enantiomers" means a pair of stereoisomers that are non-superimposable mirror images of one another.

[0230] "Diastereomers" or "diastereomers" means optical isomers that are not mirror images of one another.

[0231] "Racemic mixture" or "racemate" means a mixture containing equal parts of the individual enantiomers.

[0232] "Non-racemic mixture" means a mixture containing unequal parts of the individual enantiomers.

[0233] "Geometric isomers" means stable isomers resulting from rotational freedom restrictions in double bonds (e.g., cis-2-butene and trans-2-butene) or ring structures (e.g., cis-1,3-dichlorocyclobutane and trans-1,3-dichlorocyclobutane). Because carbon-carbon double (olefinic) bonds, C=N double bonds, ring structures, etc. can be present in the compounds of the present disclosure, the present disclosure contemplates each of the different stable geometric isomers and mixtures thereof resulting from the arrangement of substituents around these double bonds and in these ring structures. Substituents and isomers are represented using the cis / trans convention or using the E or Z system, where the term "E" means that higher-order substituents are on opposite sides of the double bond and the term "Z" means that higher-order substituents are on the same side of the double bond. A detailed discussion of E and Z isomerism is provided in J. March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 4th ed., John Wiley & Sons, 1992, which is hereby incorporated by reference in its entirety. Several of the following examples represent single E isomers, single Z isomers, and mixtures of E / Z isomers. Determination of E and Z isomers can be performed by analytical methods, such as X-ray crystallography, 1 HNMR, and 13 C NMR.

[0234] Some compounds of the present disclosure can exist in more than one tautomeric form. As mentioned above, the compounds of the present disclosure include all such tautomers.

[0235] It is well known in the art that the biological and pharmacological activities of a compound are sensitive to the stereochemistry of the compound. Thus, for example, enantiomers typically exhibit significantly different biological activities, including differences in pharmacokinetic properties (including metabolism, protein binding, etc.) and pharmacological properties (including the type of activity exhibited, the degree of activity, toxicity, etc.). Thus, one skilled in the art will understand that one enantiomer may be more active or may exhibit a beneficial effect when enriched relative to the other enantiomer or when separated from the other enantiomer. Additionally, one skilled in the art will know how to separate, enrich, or selectively prepare the enantiomers of the compounds of the present disclosure from the knowledge of the present disclosure and the prior art.

[0236] Therefore, although the racemic form of a drug can be used, it is generally not as effective as administering an equal amount of the enantiomerically pure drug; in fact, in some cases, one enantiomer may be pharmacologically inactive and merely act as a simple diluent. For example, although ibuprofen has previously been administered as a racemate, it has been found that only the S-isomer of ibuprofen is effective as an anti-inflammatory agent (however, in the case of ibuprofen, although the R-isomer is inactive, it is converted to the S-isomer in the body, so the racemic form of the drug is slower to take effect than the pure S-isomer). In addition, the pharmacological activity of enantiomers can have significantly different biological activities. For example, S-penicillamine is a therapeutic agent for chronic arthritis, while R-penicillamine is toxic. In fact, some purified enantiomers have advantages over the racemate, as it has been reported that purified individual isomers have faster transdermal penetration rates than the racemic mixture. See U.S. Patent Nos. 5,114,946 and 4,818,541.

[0237] Therefore, if one enantiomer is pharmacologically more active, less toxic, or has a more favorable body distribution than the other enantiomer, it would be therapeutically more beneficial to administer that enantiomer preferentially. In this way, the treated patient would be exposed to a lower total dose of the drug and a lower dose of the potentially toxic enantiomer or other enantiomer inhibitors.

[0238] The preparation of pure enantiomers or mixtures having the desired enantiomeric excess (ee) or enantiomeric purity can be accomplished by one or more of a number of methods known to those skilled in the art for (a) separation or resolution of enantiomers, or (b) enantioselective synthesis, or a combination of these methods. These resolution methods generally rely on chiral recognition and include, for example, chromatography using chiral stationary phases, enantioselective host-guest complexation, resolution or synthesis using chiral auxiliaries, enantioselective synthesis, enzymatic and non-enzymatic kinetic resolution, or spontaneous enantioselective crystallization. Such methods are generally disclosed in: Chiral Separation Techniques: A Practical Approach (2nd ed.), G. Subramanian (ed.), Wiley-VCH, 2000; TE Beesley and RPW Scott, Chiral Chromatography, John Wiley & Sons, 1999; and Satinder Ahuja, Chiral Separations by Chromatography, Am. Chem. Soc., 2000. In addition, there are also well-known methods for quantifying enantiomeric excess or purity (e.g., GC, HPLC, CE, or NMR) and for identifying absolute configuration and conformation (e.g., CDORD, X-ray crystallography, or NMR).

[0239] In general, all tautomeric and isomeric forms and mixtures of a chemical structure or compound, whether individual geometric isomers or stereoisomers or racemic or non-racemic mixtures, are contemplated unless a specific stereochemistry or isomeric form is explicitly indicated in the compound name or structure.

[0240] D. Drug Administration and Treatment Terminology and Conventions

[0241] A "patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.

[0242] "Effective amount" or "therapeutically effective amount," when used in reference to a compound, means an amount of a compound of the present disclosure that (i) treats or prevents a particular disease, condition, or disorder, (ii) reduces, alleviates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein.

[0243] The term "pharmaceutically effective amount" or "therapeutically effective amount" means an amount of a compound according to the present disclosure that, when administered to a patient in need thereof, is sufficient to achieve treatment of the disease state, condition, or disorder in which the compound has utility. Such an amount is sufficient to elicit the biological or medical response of the tissue, system, or patient sought by the researcher or clinician. The amount of a compound according to the present disclosure that constitutes a therapeutically effective amount will vary according to factors such as the compound and its biological activity, the composition for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of treatment, the type of disease state or disorder being treated and its severity, the drugs used in combination or together with the compound of the present disclosure, and the patient's age, weight, general health, sex, and diet. Such a therapeutically effective amount can be routinely determined by those of ordinary skill in the art based on their own knowledge, the prior art, and the present disclosure.

[0244] As used herein, the term "pharmaceutical composition" refers to a compound of the present disclosure or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in a form suitable for oral or parenteral administration, and at least one pharmaceutically acceptable carrier.

[0245] "Carrier" encompasses vehicles, excipients, and diluents, and means a material, composition, or vehicle involved in carrying or transporting a pharmaceutical agent from one organ or part of a subject's body to another, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.

[0246] A subject (preferably a human) is "in need of" a treatment if the subject would benefit biologically, medically, or in quality of life from such treatment.

[0247] As used herein, the terms "inhibit," "inhibition," or "inhibiting" refer to the reduction or suppression of a given condition, symptom or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.

[0248] As used herein, the terms "treat," "treating," or "treatment" of any disease or disorder refers to alleviating or relieving the disease or disorder (i.e., slowing or arresting the progression of the disease or at least one clinical symptom thereof); or alleviating or relieving at least one physical parameter or biomarker associated with the disease or disorder, including those that may not be discernible by the patient.

[0249] As used herein, the terms "prevent," "preventing," or "prevention" of any disease or disorder refers to prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.

[0250] "Pharmaceutically acceptable" means that the substance or composition must be compatible chemically and / or toxicologically with the other ingredients comprising the formulation and / or the mammal being treated therewith.

[0251] Unless otherwise indicated, "disorder" is intended to refer to the term disease, condition, or ailment and is used interchangeably with these terms.

[0252] "Administer," "administering," or "administration" means administering a disclosed compound, or a pharmaceutically acceptable salt or composition of a disclosed compound, directly to a subject, or administering a prodrug derivative or analog of a compound, or a pharmaceutically acceptable salt or composition of a compound to a subject, which can form an equivalent amount of the active compound in the subject.

[0253] "Prodrug" means a compound that is convertible in vivo by metabolic means (eg, by hydrolysis) to a disclosed compound.

[0254] "Compounds of the present disclosure," "compounds of formula (I')," "compounds of the disclosure," and equivalent expressions (unless otherwise specifically indicated) refer to compounds of formula (I'), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (Ia-1), (Ib-1), (Ic-1), (Id-1), (Ie-1), (If-1), (Ig-1), (Ih-1), (Ii-1), (Ij-1), (Ik-1), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (Ia-1), (Ib-1), (Ic-1), (Id-1), (Ie-1), (If-1), (Ig-1), (Ih-1), (Ii-1), (Ij-1), (Ik-1), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (Ia-1), (Ib-1), (Ic-1), (Id-1), (Ie-1), (If-1), (Ig-1), (Ih-1), (Ii-1), (Ij-1), (Ik-1), (Im), (In), l-1), (Im-1), (In-1), (Io-1), (Ip-1), (Iq-1), (Ir-1), (Is-1), (It-1), (Ia-2), (Ia-3), (Ib-2), and / or (Ib-3) compounds, including their tautomers, prodrugs, salts (particularly pharmaceutically acceptable salts), and solvates and hydrates, (where the context permits) as well as all stereoisomers (including diastereomers and enantiomers), rotational isomers, tautomers, and isotopically labeled compounds (including deuterium substitution), as well as inherently formed moieties (e.g., polymorphs, solvates and / or hydrates). For the purposes of this disclosure, solvates and hydrates are generally considered to be compositions. Generally and preferably, the compounds of the present disclosure and formulas representing the compounds of the present disclosure should be understood to include only stable compounds thereof and exclude unstable compounds, even if unstable compounds can be considered to be actually included in the compound formula. Similarly, references to intermediates (whether or not they themselves are claimed) are intended to include their salts and solvates, where the context permits. For clarity, specific instances where the context permits are sometimes indicated in the text, but these are purely illustrative and are not intended to exclude other instances where the context permits.

[0255] By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic or diagnostic agent. For example, compounds with "dangling valencies" or carbanions are not contemplated by the present disclosure.

[0256] In particular embodiments, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0257] The yield for each reaction described herein is expressed as a percentage of the theoretical yield. "Cancer" means any cancer caused by malignant neoplastic cell proliferation, such as a tumor, neoplasm, carcinoma, sarcoma, leukemia, lymphoma, and the like. For example, cancers include, but are not limited to, mesothelioma, leukemia, and lymphoma, such as cutaneous T-cell lymphoma (CTCL), non-cutaneous peripheral T-cell lymphoma, lymphomas associated with human T-cell lymphotropic virus (HTLV) such as adult T-cell leukemia / lymphoma (ATLL), B-cell lymphoma, acute non-lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, lymphoma and multiple myeloma, non-Hodgkin's lymphoma, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma, Burkitt's lymphoma, adult T-cell leukemia lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or hepatocellular carcinoma. Additional examples include myelodysplastic syndrome, solid tumors in children (e.g., brain tumors, neuroblastoma, retinoblastoma, Wilms' tumor, bone tumors, and soft tissue sarcomas), common solid tumors in adults (e.g., head and neck cancers, such as cancers of the mouth, larynx, nasopharynx, and esophagus), genitourinary cancers (e.g., cancers of the prostate, bladder, kidney, uterus, ovary, testicle), lung cancer (e.g., small cell and non-small cell lung cancer), breast cancer (e.g., triple-negative breast cancer (TNBC)), pancreatic cancer, melanoma, and other skin cancers, gastric cancer, brain tumors, tumors associated with Gorlin's syndrome (e.g., medulloblastoma, meningioma, etc.), and liver cancer. Additional exemplary forms of cancer that can be treated by the subject compounds include, but are not limited to, cancers of skeletal or smooth muscle, gastric cancer, cancer of the small intestine, rectal cancer, cancer of the salivary glands, endometrial cancer, adrenal cancer, anal cancer, rectal cancer, parathyroid cancer, and pituitary cancer.

[0258] Compounds described herein can be used to prevent, treat, and study additional cancers such as colon cancer, familial adenomatous polyposis, and hereditary non-polyposis colorectal cancer, or melanoma. In addition, cancers include, but are not limited to, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, stomach cancer, adenocarcinoma, thyroid cancer (medullary and papillary thyroid cancer), kidney cancer, renal parenchymal cancer, cervical cancer, uterine corpus cancer, endometrial cancer, choriocarcinoma, testicular cancer, urinary system cancer, melanoma, brain tumors (e.g., glioblastoma, astrocytoma, meningioma, medulloblastoma, and peripheral neuroectodermal tumor), gallbladder cancer, bronchogenic carcinoma, multiple myeloma, basal cell tumor , teratoma, retinoblastoma, choroidal melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, plasmacytoma, non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).

[0259] When referring to a method of treatment or means of therapeutic use of a combination of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and one or more second agents, "simultaneously" or "concurrently" means administering the compound and the one or more second agents by the same route and at the same time.

[0260] When referring to a method of treatment or means of therapeutic use using a combination of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and one or more second agents, "separately" or "separately" means administering the compound and the one or more second agents by different routes and at approximately the same time.

[0261] When referring to the therapeutic method or therapeutic use of the combination of a compound with formula (I) or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer and one or more second agents, "over a period of time" therapeutic administration is to administer the compound and the one or more second agents by the same or different routes and at different times. In certain embodiments, the administration of the compound or one or more second agents occurs before the administration of other substances begins. In this way, before administering one or more other active ingredients, one of several months' active ingredients (that is, a compound with formula (I) or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer, or one or more second agents) can be administered. In this case, simultaneous administration will not occur. Another type of therapeutic administration over a period of time consists of administering two or more active ingredients of a combination over time (using different administration frequencies for each active ingredient) such that at certain time points all of the active ingredients are administered simultaneously, while at other time points only a portion of the active ingredients of the combination may be administered (such as, for example, a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more second agents, where therapeutic administration over a period of time can result in the compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, being administered once daily and the one or more second agents being administered once every four weeks).

[0262] The compounds can be administered simultaneously (as a single formulation or separate formulations) sequentially, separately or over a period of time to other drug therapies or treatment modalities.In general, combination therapy envisions the administration of two or more drugs during a single cycle or course of treatment.

[0263] "IKZF2-dependent disease or disorder" means any disease or disorder that is directly or indirectly affected by modulation of IKZF2 protein levels.

[0264] "IKZF4-dependent disease or disorder" means any disease or disorder that is directly or indirectly affected by modulation of IKZF4 protein levels.

[0265] D. Specific Examples and Methods for Testing Compounds of Formula (I') or Formula (I)

[0266] The present disclosure relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof that can modulate IKZF2 protein levels (useful for treating diseases and disorders associated with modulation of IKZF2 protein levels). The present disclosure further relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof that can reduce or decrease IKZF2 protein levels.

[0267] In one embodiment, the compound of formula (I') or formula (I) has the following structure: Formula (Ia) or formula (Ia-1):

[0268]

[0269] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0270] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Ib) or formula (Ib-1):

[0271]

[0272] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0273] In one embodiment, the compound of formula (I') has the following structure: Formula (Ia-2) or Formula (Ia-3):

[0274]

[0275] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0276] In another embodiment, the compound of formula (I') has the following structure: Formula (Ib-2) or Formula (Ib-3):

[0277]

[0278] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0279] In yet another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (lc) or formula (lc-1):

[0280]

[0281] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0282] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Id) or formula (Id-1):

[0283]

[0284] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0285] In another embodiment, the compound of formula (I') or formula (I) has the following structure: Formula (Ie) or formula (Ie-1):

[0286]

[0287] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0288] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (If) or formula (If-1):

[0289]

[0290] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0291] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Ig) or formula (Ig-1):

[0292]

[0293] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0294] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Ih) or formula (Ih-1):

[0295]

[0296] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0297] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Ii) or formula (Ii-1):

[0298]

[0299] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0300] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Ij) or formula (Ij-1):

[0301]

[0302] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0303] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Ik) or formula (Ik-1):

[0304]

[0305] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0306] In another embodiment, the compound of formula (I') or formula (I) has the following structure: Formula (Il) or formula (Il-1):

[0307]

[0308] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0309] In another embodiment, the compound of formula (I') or formula (I) has the following structure: Formula (Im) or formula (Im-1):

[0310]

[0311] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0312] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (In) or formula (In-1):

[0313]

[0314] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0315] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Io) or formula (Io-1):

[0316]

[0317] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0318] In another embodiment, the compound of formula (I') or formula (I) has the following structure: Formula (Ip) or formula (Ip-1):

[0319]

[0320] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0321] In another embodiment, the compound of formula (I') or formula (I) has the following structure: Formula (Iq) or formula (Iq-1):

[0322]

[0323] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0324] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Ir) or formula (Ir-1):

[0325]

[0326] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0327] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (Is) or formula (Is-1):

[0328]

[0329] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0330] In another embodiment, the compound of formula (I') or formula (I) has the following structure: formula (It) or formula (It-1):

[0331]

[0332] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0333] In some embodiments of the above formula (e.g., Formula (I'), (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (Ia-1), (Ib-1), (Ic-1), (Id-1), (Ie-1), (If-1), (Ig-1), (Ih-1), (Ii-1), (Ij-1), (Ik-1), (Il-1), (Im-1), (In-1), (Io-1), (Ip-1), (Iq-1), (Ir-1), (Is-1), (It-1), (Ia-2), (Ia-3), (Ib-2), and / or (Ib-3),

[0334] ), R1 is In another embodiment, R1 is In yet another embodiment, R1 is

[0335] In another embodiment, R1 is In yet another embodiment, R1 is In another embodiment, R1 is

[0336] In some embodiments of the above formula, each R a and R b is independently H or D. In another embodiment, each R a and R b are independently H, or R a and R b Together with the atoms to which they are attached, they form =(O). In yet another embodiment, each R a and R b is independently H. In another embodiment, or R a and R b Together with the atoms to which they are attached they form =(O).

[0337] In some embodiments of the above formula, X 1 is H, (C 1 -C 3) alkyl, (C 1 -C 6) alkoxy, (C 1 -C 3) haloalkyl, (C 1 -C 6) haloalkoxy, (C 3 -C 7) cycloalkyl, halogen, CN, -OH, or -NH 2. In another embodiment, X 1 is H, (C 1 -C 3) alkyl, (C 1 -C 6) alkoxy, (C 1 -C 3) haloalkyl, (C 1 -C 3) haloalkoxy, halogen, CN, -OH, or -NH 2. In yet another embodiment, X 1 is H, (C 1 -C 4) alkyl, (C 1 -C 6) alkoxy, (C 1 -C 4) haloalkyl, (C 1 -C 4) haloalkoxy, (C 3 -C 7) cycloalkyl, or halogen. In another embodiment, X 1 is H, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy, (C 1 -C 4) haloalkyl, (C 1 -C 4) haloalkoxy, or halogen. In yet another embodiment, X 1 is H, halogen, CN, -OH, or -NH 2. In another embodiment, X 1 is H, (C 1 -C 4) alkyl, (C 1 -C 4) haloalkyl, halogen, CN, -OH, or -NH 2. In yet another embodiment, X 1 is H, (C 1 -C 4) alkyl, (C 1 -C 4) haloalkyl, halogen, -OH, or -NH 2. In another embodiment, X 1 is H, (C 1 -C 4) alkyl, halogen, -OH, or -NH 2. In yet another embodiment, X 1 is H, halogen, -OH, or -NH 2. In another embodiment, X 1 is H, halogen, -OH, or -NH 2. In another embodiment, X 1 is H.

[0338] In some embodiments of the above formula, X2 is H, (C1-C3) alkyl, (C1-C6) alkoxy, (C1-C3) haloalkyl, (C1-C6) haloalkoxy, (C3-C7) cycloalkyl, halogen, CN, -OH, or -NH2. In another embodiment, X2 is H, (C1-C3) alkyl, (C1-C6) alkoxy, (C1-C3) haloalkyl, (C1-C3) haloalkoxy, halogen, CN, -OH, or -NH2. In yet another embodiment, X2 is H, (C1-C4) alkyl, (C1-C6) alkoxy, (C1-C4) haloalkyl, (C1-C4) haloalkoxy, (C3-C7) cycloalkyl, or halogen. In another embodiment, X2 is H 、(In yet another embodiment, X is H, halogen, CN, -OH, or -NH. In another embodiment, X is H, (C-C)alkyl, (C-C)haloalkyl, halogen, CN, -OH, or -NH. In yet another embodiment, X is H, (C-C)alkyl, (C-C)haloalkyl, halogen, -OH, or -NH. In yet another embodiment, X is H, (C-C)alkyl, (C-C)haloalkyl, halogen, -OH, or -NH. In yet another embodiment, X is H, (C-C)alkyl, (C-C)haloalkyl, halogen, -OH, or -NH. In yet another embodiment, X is H, (C-C)alkyl, halogen, -OH, or -NH. In yet another embodiment, X is H, halogen, -OH, or -NH. In yet another embodiment, X is H, halogen, -OH, or -NH. In yet another embodiment, X is H.

[0339] In some embodiments of the above formula, X1 is H, and X2 is (C1-C3)alkyl, (C1-C6)alkoxy, (C1-C3)haloalkyl, (C1-C6)haloalkoxy, (C3-C7)cycloalkyl, halogen, CN, -OH, or -NH2. In another embodiment, X1 is (C1-C3)alkyl, (C1-C6)alkoxy, (C1-C3)haloalkyl, (C1-C6)haloalkoxy, (C3-C7)cycloalkyl, halogen, CN, -OH, or -NH2 and X2 is H. In yet another embodiment, X1 is H and X2 is H.

[0340] In some embodiments of the above formula, R x is D. In another embodiment, R x It’s H.

[0341] In some embodiments of the above formula, R2 is H, (C1-C3)alkyl, (C1-C3)haloalkyl, or (C3-C6)cycloalkyl. In another embodiment, R2 is (C1-C3)alkyl, (C1-C3)haloalkyl, or (C3-C6)cycloalkyl. In yet another embodiment, R2 is H, (C1-C3)alkyl, or (C3-C6)cycloalkyl. In another embodiment, R2 is H, (C1-C3)alkyl, or (C1-C3)haloalkyl. In yet another embodiment, R2 is H or (C1-C3)alkyl. In another embodiment, R2 is H, methyl, ethyl, n-propyl, or isopropyl. In yet another embodiment, R2 is H, methyl, or ethyl. In another embodiment, R2 is H or methyl.

[0342] In some embodiments of the above formula, R2 and R7 together with the nitrogen atom to which they are attached form a 7-membered heterocycloalkyl ring. In another embodiment, R2 and R7 together with the nitrogen atom to which they are attached form a 6-membered heterocycloalkyl ring.

[0343] In some embodiments of the above formula, each R3 is independently, at each occurrence, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, halogen, CN, -OH, or -NH2. In another embodiment, R3 is independently, at each occurrence, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, or halogen. In yet another embodiment, R3 is independently, at each occurrence, halogen, CN, -OH, or -NH2. In another embodiment, R3 is independently, at each occurrence, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, or (C1-C3)haloalkoxy. In yet another embodiment, R3 is independently at each occurrence (C1-C3)alkyl, (C1-C3)haloalkyl, halogen, CN, -OH, or -NH2. In another embodiment, R3 is independently at each occurrence (C1-C3)alkyl, (C1-C3)haloalkyl, halogen, or CN. In yet another embodiment, R3 is independently at each occurrence (C1-C3)alkyl, halogen, or CN. In another embodiment, R3 is independently at each occurrence (C1-C3)alkyl or (C1-C3)haloalkyl. In yet another embodiment, R3 is independently at each occurrence (C1-C3)alkyl or CN. In another embodiment, R3 is independently at each occurrence (C1-C3)alkyl. In yet another embodiment, R3 is independently at each occurrence methyl, ethyl, n-propyl, or isopropyl.

[0344] In some embodiments of the above formula, two R3, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S; or when two R3 are on adjacent carbon atoms, together form a phenyl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, two R3, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl or a 5- or 6-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, two R3, together with the carbon atom to which they are attached, form a (C4-C7)cycloalkyl or a 5- or 6-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3, together with the carbon atom to which they are attached, form a (C5-C7)cycloalkyl or a 5- or 6-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S.

[0345] In another embodiment, two R3 together with the carbon atom to which they are attached form a (C3-C7) cycloalkyl group. In another embodiment, two R3 together with the carbon atom to which they are attached form a (C4-C7) cycloalkyl group. In yet another embodiment, two R3 together with the carbon atom to which they are attached form a (C5-C7) cycloalkyl group. In another embodiment, two R3 together with the carbon atom to which they are attached form a 4- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3 together with the carbon atom to which they are attached form a 5- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3 together with the carbon atom to which they are attached form a 5- or 6-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S.

[0346] In another embodiment, when two R3 are on adjacent carbon atoms, they form together a phenyl group, or a 5-membered or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, when two R3 are on adjacent carbon atoms, they form together a phenyl group or a 5-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, when two R3 are on adjacent carbon atoms, they form together a phenyl group or a 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, when two R3 are on adjacent carbon atoms, they form together a phenyl group. In yet another embodiment, when two R3 are on adjacent carbon atoms, they form together a phenyl group. In yet another embodiment, when two R3 are on adjacent carbon atoms, they form together a 5-membered or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3 when on adjacent carbon atoms are taken together to form a 5-membered heteroaryl ring comprising 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, two R3 when on adjacent carbon atoms are taken together to form a 6-membered heteroaryl ring comprising 1-3 heteroatoms selected from O, N, and S.

[0347] In another embodiment, two R3, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group; or when two R3 are on adjacent carbon atoms, together form a phenyl group, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, two R3, together with the carbon atom to which they are attached, form a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S; or when two R3 are on adjacent carbon atoms, together form a phenyl group, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl group or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, or when two R3 are on adjacent carbon atoms, form a phenyl group. In yet another embodiment, two R3, together with the carbon atom to which they are attached, form a (C3-C7)cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S; or when two R3 are on adjacent carbon atoms, together form a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S.

[0348] In another embodiment, the two R3 together with the carbon atoms to which they are attached form a (C3-C7) cycloalkyl group or when the two R3 are on adjacent carbon atoms, form a phenyl group. In another embodiment, the two R3 together with the carbon atoms to which they are attached form a (C4-C7) cycloalkyl group or when the two R3 are on adjacent carbon atoms, form a phenyl group. In another embodiment, the two R3 together with the carbon atoms to which they are attached form a (C5-C7) cycloalkyl group or when the two R3 are on adjacent carbon atoms, form a phenyl group.

[0349] In another embodiment, two R3, together with the carbon atoms to which they are attached, form a 4- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S; or when two R3 are on adjacent carbon atoms, together form a 5- or 6-membered heteroaryl ring comprising 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, two R3, together with the carbon atoms to which they are attached, form a 5- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S; or when two R3 are on adjacent carbon atoms, together form a 5- or 6-membered heteroaryl ring comprising 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3 together with the carbon atom to which they are attached form a 5- or 6-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S; or when two R3 are on adjacent carbon atoms, together form a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S.

[0350] In another embodiment, two R3, when attached to the same carbon atom, form together a (C3-C7) spirocycloalkyl or a 4- to 7-membered spiroheterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3, when on adjacent carbon atoms, form a (C3-C7) cycloalkyl or a 4- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R3, together with the carbon atom to which they are attached, form a bridged (C3-C7) cycloalkyl or a 4- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S.

[0351] In some embodiments of the above formula, R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, and optionally substituted with one to four substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, and halogen. In another embodiment, R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, and substituted with one to four substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, and halogen. In another embodiment, R3 and R7 together with the nitrogen atom and the carbon atom to which they are attached form a 5- or 6-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S.

[0352] In some embodiments of the above formula, each R4 is (C1-C6)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, halogen, -OH, or -NH2. In another embodiment, R4 is (C1-C6)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, or halogen. In another embodiment, R4 is (C1-C6)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, or (C1-C3)haloalkoxy. In another embodiment, R4 is (C1-C6)alkyl, (C1-C3)haloalkyl, or halogen. In another embodiment, R4 is halogen, -OH, or -NH2. In another embodiment, R4 is (C1-C6)alkyl, (C1-C3)haloalkyl, halogen, -OH, or -NH2. In another embodiment, R4 is (C1-C6)alkyl, (C1-C3)haloalkyl, halogen, or -OH. In another embodiment, R4 is (C1-C6)alkyl or (C1-C3)haloalkyl. In another embodiment, R4 is (C1-C6)alkyl.

[0353] In some embodiments of the above formula, R5 is -OR6. In another embodiment, R5 is -NR7R 7’ .

[0354] In some embodiments of the above formula, R6 is H, (C1-C3) alkyl, (C1-C3) haloalkyl, -C(O)(C1-C3) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R6 is (C1-C3)alkyl, (C1-C3)haloalkyl, -C(O)(C1-C3)alkyl, (C3-C7)cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0355] In another embodiment, R6 is H, (C1-C3) alkyl, (C1-C3) haloalkyl, -C(O)(C1-C3) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In yet another embodiment, R6 is (C1-C3)alkyl, (C1-C3)haloalkyl, -C(O)(C1-C3)alkyl, (C3-C7)cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0356] In another embodiment, R6 is H, (C1-C3) alkyl, (C1-C3) haloalkyl, or -C(O)(C1-C3) alkyl, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10)aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In yet another embodiment, R6 is (C1-C6)alkyl, (C1-C3)haloalkyl, or -C(O)(C1-C3)alkyl, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R6 is (C3-C7)cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 )aryl, or a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0357] In another embodiment, R6 is H, (C1-C3) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In yet another embodiment, R6 is H, (C1-C3)alkyl, (C3-C7)cycloalkyl, or a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0358] In another embodiment, R6 is H, (C1-C3) alkyl, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In yet another embodiment, R6 is H, (C1-C3)alkyl, (C3-C7)cycloalkyl, or (C6-C 10 ) aryl, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0359] In another embodiment, R6 is H, (C1-C3)alkyl, (C3-C7)cycloalkyl, or (C6-C 10 ) aryl, wherein the alkyl group is optionally substituted by one to three (C6-C 10 In yet another embodiment, R6 is H, (C1-C3) alkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R6 is H, (C1-C3)alkyl, (C3-C7)cycloalkyl, or (C6-C 10 ) aryl, wherein the alkyl group is optionally substituted by one to three (C6-C 10 ) aryl substituted.

[0360] In some embodiments of the above formula, R7 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 In another embodiment, R7 is H, (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 In yet another embodiment, R7 is (C1-C6)alkyl, (C1-C3)haloalkyl, (C3-C7)cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11In another embodiment, R7 is H, (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 replace.

[0361] In another embodiment, R7 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 )aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted with one to three R8. In another embodiment, R7 is H, (C1-C6)alkyl, (C1-C3)haloalkyl, (C3-C7)cycloalkyl, a 5- or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 )aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted with one to three R8. In yet another embodiment, R7 is (C1-C6)alkyl, (C1-C3)haloalkyl, (C3-C7)cycloalkyl, a 5- or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 )aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted with one to three R8. In another embodiment, R7 is H, (C1-C6)alkyl, (C1-C3)haloalkyl, (C3-C7)cycloalkyl, a 5- or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is substituted by one to three R8.

[0362] In another embodiment, R7 is (C1-C6)alkyl, (C1-C3)haloalkyl, (C3-C7)cycloalkyl, 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11In yet another embodiment, R7 is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 In another embodiment, R7 is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, or a 5- or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, and heterocycloalkyl are optionally substituted with one to four R8. 11 In yet another embodiment, R7 is H, (C1-C6) alkyl, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the aryl and heteroaryl are optionally substituted with one to four R 11 replace.

[0363] In another embodiment, R7 is (C1-C6)alkyl, (C1-C3)haloalkyl, (C3-C7)cycloalkyl, 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 )aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl group is substituted with one to three R8. In yet another embodiment, R7 is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, a 5- or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 ) aryl, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted with one to three R8. In another embodiment, R7 is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, or a 5- or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted with one to three R8. In yet another embodiment, R7 is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, or a 5- or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted with one to three R8. 10 )aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8.

[0364] In another embodiment, R7 is H, (C1-C6) alkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the heterocycloalkyl and heteroaryl are optionally substituted with one to four R8. 11 In yet another embodiment, R7 is H, (C1-C6)alkyl, (C1-C3)haloalkyl, (C3-C7)cycloalkyl, or (C6-C 10 )aryl, wherein the alkyl is optionally substituted with one to three R8. In another embodiment, R7 is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, or (C6-C 10 ) aryl, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl and aryl are optionally substituted with one to four R 11 replace.

[0365] In another embodiment, R7 is H, (C1-C6)alkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl group is optionally substituted with one to three R8. In yet another embodiment, R7 is H, (C1-C6)alkyl, (C1-C3)haloalkyl, (C3-C7)cycloalkyl, or (C6-C 10 )aryl, wherein the alkyl is optionally substituted with one to three R8. In another embodiment, R7 is H, (C1-C6)alkyl, (C3-C7)cycloalkyl, or (C6-C 10 )aryl, wherein the alkyl is optionally substituted with one to three R8.

[0366] In some embodiments of the above formula, R 7’ is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 In another embodiment, R 7’ is H, (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 In yet another embodiment, R 7’ is (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 In another embodiment, R 7’ is H, (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 replace.

[0367] In another embodiment, R 7’ is H, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl group is optionally substituted with one to three R8. In another embodiment, R 7’ is H, (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl group is optionally substituted with one to three R8. In yet another embodiment, R 7’ is (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl group is optionally substituted with one to three R8. In another embodiment, R7’ is H, (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10 )aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is substituted by one to three R8.

[0368] In another embodiment, R 7’ is (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 In yet another embodiment, R 7’ is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 In another embodiment, R 7’ is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, or a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, and heterocycloalkyl are optionally substituted with one to four R 11 In yet another embodiment, R 7’ is H, (C1-C6) alkyl, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the aryl and heteroaryl are optionally substituted with one to four R 11 replace.

[0369] In another embodiment, R 7’ is (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S, (C6-C 10) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl group is substituted with one to three R8. In yet another embodiment, R 7’ is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl group is optionally substituted with one to three R8. In another embodiment, R 7’ is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, or a 5- or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N, and S, wherein the alkyl is optionally substituted with one to three R8. In yet another embodiment, R 7’ is H, (C1-C6) alkyl, (C6-C 10 )aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8.

[0370] In another embodiment, R 7’ is H, (C1-C6) alkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the heterocycloalkyl and heteroaryl are optionally substituted with one to four R 11 In yet another embodiment, R 7’ is H, (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, or (C6-C 10 ) aryl, wherein the alkyl group is optionally substituted with one to three R8. In another embodiment, R 7’ is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, or (C6-C 10 ) aryl, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl and aryl are optionally substituted with one to four R 11 replace.

[0371] In another embodiment, R 7’ is H, (C1-C6) alkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8. In yet another embodiment, R 7’ is H, (C1-C6) alkyl, (C1-C3) haloalkyl, (C3-C7) cycloalkyl, or (C6-C10 ) aryl, wherein the alkyl group is optionally substituted with one to three R8. In another embodiment, R 7’ is H, (C1-C6) alkyl, (C3-C7) cycloalkyl, or (C6-C 10 )aryl, wherein the alkyl group is optionally substituted with one to three R8. In yet another embodiment, R 7’ is H or (C1-C6) alkyl, wherein the alkyl is optionally substituted with one to three R8. 7’ is H or (C1-C6)alkyl, wherein the alkyl is substituted with one to three R8. In yet another embodiment, R 7’ is H or (C1-C6) alkyl.

[0372] In some embodiments of the above formula, R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, which is optionally substituted with one to four R9. In another embodiment, R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, which is optionally substituted with one to three R9. In yet another embodiment, R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 5- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, which is optionally substituted with one to three R9. In another embodiment, R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 4- or 5-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to three R9. In yet another embodiment, R7 and R 7’ Together with the nitrogen atom to which they are attached they form a 5- or 6-membered heterocycloalkyl ring, which optionally contains 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted by one to three R9.

[0373] In another embodiment, R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 6- or 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to three R9. In yet another embodiment, R7 and R 7’Together with the nitrogen atom to which they are attached, they form a 4-membered heterocycloalkyl ring, which optionally contains 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to three R9. In another embodiment, R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 5-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to three R9. In yet another embodiment, R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 6-membered heterocycloalkyl ring, which optionally contains 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to three R9. In another embodiment, R7 and R 7’ Together with the nitrogen atom to which they are attached they form a 7-membered heterocycloalkyl ring, which optionally contains 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to three R9.

[0374] In some embodiments of the above formula, R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, and optionally substituted with one to four substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, and halogen. In another embodiment, R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, and substituted with one to four substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, and halogen. In yet another embodiment, R3 and R7 together with the nitrogen atom and the carbon atom to which they are attached form a 5- or 6-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S.

[0375] In another embodiment, R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5-membered heterocycloalkyl ring, optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, which is optionally substituted with one to four substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, and halogen. In yet another embodiment, R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5-membered heterocycloalkyl ring, optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, which is substituted with one to four substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, and halogen. In another embodiment, R3 and R7 together with the nitrogen atom and the carbon atom to which they are attached form a 5-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S.

[0376] In another embodiment, R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 6-membered heterocycloalkyl ring, optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, which is optionally substituted with one to four substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, and halogen. In yet another embodiment, R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 6-membered heterocycloalkyl ring, optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, which is substituted with one to four substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, and halogen. In another embodiment, R3 and R7 together with the nitrogen atom and the carbon atom to which they are attached form a 6-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S.

[0377] In some embodiments of the above formula, each R8 is -C(O)OH, (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one to three R 10 In another embodiment, each R8 is -C(O)OH, (C3-C7)cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, wherein the cycloalkyl and heterocycloalkyl are optionally replaced by one to three R 10In yet another embodiment, each R8 is -C(O)OH, (C6-C 10 ) aryl or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the aryl and heteroaryl are optionally substituted by one to three R 10 replace.

[0378] In another embodiment, each R8 is (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one to three R 10 In another embodiment, each R8 is (C3-C7) cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, wherein the cycloalkyl and heterocycloalkyl are optionally substituted by one to three R 10 In yet another embodiment, each R8 is (C6-C 10 ) aryl or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the aryl and heteroaryl are optionally substituted by one to three R 10 replace.

[0379] In another embodiment, each R8 is -C(O)OH, (C3-C7)cycloalkyl, or (C6-C 10 ) aryl, wherein the cycloalkyl and aryl groups are optionally substituted by one to three R 10 In yet another embodiment, each R8 is a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S, wherein the heterocycloalkyl and heteroaryl are optionally substituted by one to three R 10 In another embodiment, each R8 is -C(O)OH, (C3-C7)cycloalkyl, or a 5- or 6-membered heteroaryl group containing 1-3 heteroatoms selected from O, N, and S, wherein the cycloalkyl and heteroaryl groups are optionally substituted by one to three R 10 In yet another embodiment, each R8 is -C(O)OH, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, or (C6-C 10 ) aryl, wherein the heterocycloalkyl and aryl groups are optionally substituted by one to three R 10 replace.

[0380] In another embodiment, each R8 is (C3-C7)cycloalkyl or (C6-C 10 ) aryl, wherein the cycloalkyl and aryl groups are optionally substituted by one to three R10 In yet another embodiment, each R8 is a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S, wherein the heterocycloalkyl and heteroaryl are optionally substituted by one to three R 10 In another embodiment, each R8 is (C3-C7) cycloalkyl or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the cycloalkyl and heteroaryl are optionally substituted by one to three R 10 In yet another embodiment, each R8 is a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, or (C6-C 10 ) aryl, wherein the heterocycloalkyl ring and aryl are optionally substituted by one to three R 10 replace.

[0381] In another embodiment, each R8 is optionally replaced by one to three R 10 In yet another embodiment, each R8 is replaced by one to three R 10 In another embodiment, each R8 is -C(O)OH, or (C3-C7)cycloalkyl. In yet another embodiment, each R8 is optionally substituted by one to three R 10 Substituted (C6-C 10 In another embodiment, each R8 is -C(O)OH, or is replaced by one to three R 10 Substituted (C6-C 10 In yet another embodiment, each R8 is -C(O)OH, or (C6-C 10 In another embodiment, each R8 is -C(O)OH.

[0382] In another embodiment, each R8 is optionally replaced by one to three R 10 In yet another embodiment, each R8 is replaced by one to three R 10 In another embodiment, each R8 is (C3-C7)cycloalkyl. In yet another embodiment, each R8 is optionally substituted by one to three R 10 Substituted (C6-C 10 In another embodiment, each R8 is replaced by one to three R 10 Substituted (C6-C 10 In yet another embodiment, each R8 is (C6-C 10 )aryl.

[0383] In another embodiment, each R8 is -C(O)OH, or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, optionally substituted by one to three R 10 In yet another embodiment, each R8 is replaced by one to three R 10 In another embodiment, each R8 is -C(O)OH or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, each R8 is -C(O)OH, or a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R8. 10 In another embodiment, each R8 is replaced by one to three R 10 substituted -C(O)OH or a 5- or 6-membered heteroaryl group containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, each R8 is -C(O)OH, or a 5- or 6-membered heteroaryl group containing 1-3 heteroatoms selected from O, N, and S.

[0384] In another embodiment, each R8 is a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, optionally substituted by one to three R 10 In yet another embodiment, each R8 is replaced by one to three R 10 In another embodiment, each R8 is a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, each R8 is a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S, which is optionally substituted by one to three R 10 In another embodiment, each R8 is replaced by one to three R 10 substituted 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, each R8 is a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S.

[0385] In some embodiments of the above formula, each R9 is independently at each occurrence halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, -OH, CN, -NR 12 R 13, or -NH2, wherein the alkoxy is optionally substituted by one to three substituents, the one to three substituents being independently selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 )aryl, and a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, each R9 is independently, at each occurrence, halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, CN, -OH, or -NH2, wherein the alkoxy is optionally substituted with one to three substituents independently selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 )aryl, and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, each R9 is independently halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, CN, -NR 12 R 13 , or -OH, wherein the alkoxy is optionally substituted by one to three substituents, the one to three substituents being independently selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 )aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0386] In another embodiment, each R9 is independently at each occurrence halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, CN, or -OH, wherein the alkoxy is optionally substituted with one to three substituents independently selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 )aryl, and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, each R9 is independently at each occurrence halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, -NR 12 R 13 , or -OH, wherein the alkoxy group is optionally replaced by (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, and (C6-C 10In another embodiment, each R is independently, at each occurrence, halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, or -OH, wherein the alkoxy is optionally substituted with (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, and (C6-C 10 ) aryl substituted.

[0387] In another embodiment, each R9, at each occurrence, is independently halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, or -OH, wherein the alkoxy is optionally substituted with one to three substituents independently selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, and a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, each R9 is independently at each occurrence halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, or -OH, wherein the alkoxy is optionally substituted with one to three substituents independently selected from (C3-C7)cycloalkyl, (C6-C4 ... 10 )aryl, and a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, each R9 is independently, at each occurrence, halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, or -OH, wherein the alkoxy is optionally substituted with one to three substituents independently selected from a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 )aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0388] In another embodiment, each R9 is independently at each occurrence halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, or -OH, wherein the alkoxy is optionally substituted with one to three substituents independently selected from (C3-C7)cycloalkyl and a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, each R9 is independently at each occurrence halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, or -OH, wherein the alkoxy is optionally substituted with one to three substituents independently selected from (C3-C7)cycloalkyl and a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. 10 )aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0389] In another embodiment, each R9, at each occurrence, is independently halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, or -OH, wherein the alkoxy is optionally substituted with one to three substituents independently selected from a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, and a 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, each R9 is independently at each occurrence halogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, halogen, CN, or -OH, wherein the alkoxy is optionally substituted with one to three substituents independently selected from (C3-C7)cycloalkyl and (C6-C 10 )aryl.

[0390] In another embodiment, each R9 is (C1-C3) alkyl, (C1-C3) haloalkyl, halogen, CN, -OH or -NH2, independently at each occurrence. In another embodiment, each R9 is (C1-C6) alkyl, (C1-C6) haloalkyl, halogen, -OH or -NH2, independently at each occurrence. In another embodiment, each R9 is (C1-C6) alkyl, (C1-C6) haloalkyl, or halogen, independently at each occurrence. In another embodiment, each R9 is (C1-C6) alkyl, (C1-C6) haloalkyl, halogen or -OH, independently at each occurrence. In another embodiment, each R9 is (C1-C6) alkyl, (C1-C6) haloalkyl, halogen or -OH, independently at each occurrence. In another embodiment, each R9 is (C1-C6) alkyl, (C1-C6) haloalkyl, halogen or -NH2, independently at each occurrence. In another embodiment, each R9 is halogen, -OH or -NH2, independently at each occurrence. In another embodiment again, each R9 is (C1-C3) alkyl, (C1-C3) haloalkyl or halogen independently at each occurrence.In another embodiment, each R9 is (C1-C6) alkyl or halogen independently at each occurrence.In another embodiment again, each R9 is halogen independently at each occurrence.

[0391] In some embodiments of the above formula, two R9, together with the atoms to which they are attached, form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring comprising 1-2 heteroatoms selected from O, N, and S. In another embodiment, two R9, together with the atoms to which they are attached, form a (C5-C7)cycloalkyl. In yet another embodiment, two R9, together with the atoms to which they are attached, form a (C5-C6)cycloalkyl. In another embodiment, two R9, together with the atoms to which they are attached, form a (C6-C7)cycloalkyl. In yet another embodiment, two R9, together with the atoms to which they are attached, form a (C5)cycloalkyl. In another embodiment, two R9, together with the atoms to which they are attached, form a (C6)cycloalkyl. In yet another embodiment, two R9, together with the atoms to which they are attached, form a (C7)cycloalkyl.

[0392] In another embodiment, two R9, together with the atoms to which they are attached, form a 5- to 7-membered heterocycloalkyl ring comprising 1-2 heteroatoms selected from O, N, and S. In yet another embodiment, two R9, together with the atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring comprising 1-2 heteroatoms selected from O, N, and S. In another embodiment, two R9, together with the atoms to which they are attached, form a 6- or 7-membered heterocycloalkyl ring comprising 1-2 heteroatoms selected from O, N, and S. In yet another embodiment, two R9, together with the atoms to which they are attached, form a 5-membered heterocycloalkyl ring comprising 1-2 heteroatoms selected from O, N, and S. In another embodiment, two R9, together with the atoms to which they are attached, form a 6-membered heterocycloalkyl ring comprising 1-2 heteroatoms selected from O, N, and S. In yet another embodiment, two R 9 , together with the atoms to which they are attached, form a 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S.

[0393] In another embodiment, two R9, when attached to the same carbon atom, together form a (C5-C7) spirocycloalkyl or a 5- to 7-membered spiroheterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R9, when on adjacent carbon atoms, form a (C5-C7) cycloalkyl or a 5- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S. In another embodiment, two R9, together with the carbon atom to which they are attached, form a bridged (C5-C7) cycloalkyl or a 5- to 7-membered heterocycloalkyl ring comprising 1-3 heteroatoms selected from O, N, and S.

[0394] In some embodiments of the above formula, each R 10 is independently (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 10 is independently (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, or CN at each occurrence. In another embodiment, each R 10 is independently (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C6)alkoxy, halogen, or CN at each occurrence. In yet another embodiment, each R 10 is independently halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 10is independently (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, or halogen at each occurrence. 10 is independently (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C6)alkoxy, or halogen at each occurrence. 10 is independently (C1-C3)alkyl, (C1-C3)haloalkyl, or halogen at each occurrence. In yet another embodiment, each R 10 is independently (C1-C3)alkyl, (C1-C3)haloalkyl, or CN at each occurrence. In another embodiment, each R 10 is independently (C1-C3)alkyl or (C1-C3)haloalkyl at each occurrence. In yet another embodiment, each R 10 is independently halogen or CN at each occurrence. In another embodiment, each R 10 is independently (C1-C3)alkyl or halogen at each occurrence. In yet another embodiment, each R 10 is independently at each occurrence (C1-C3)haloalkyl.

[0395] In another embodiment, each R 10 is independently (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 10 is independently (C1-C3)alkyl, (C1-C3)haloalkyl, halogen, or CN at each occurrence. In yet another embodiment, each R 10 is independently halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 10 is independently (C1-C3)alkyl, (C1-C3)haloalkyl, or halogen at each occurrence. In yet another embodiment, each R 10 is independently (C1-C3)alkyl, (C1-C3)haloalkyl, or CN at each occurrence. In another embodiment, each R 10 is independently (C1-C3)alkyl or (C1-C3)haloalkyl at each occurrence. In yet another embodiment, each R 10 is independently halogen or CN at each occurrence. In another embodiment, each R 10 is independently (C1-C3)alkyl or halogen at each occurrence. In yet another embodiment, each R 10 is independently at each occurrence (C1-C3)haloalkyl.

[0396] In some embodiments of the above formula, the two R 10 Together with the atoms to which they are attached, they form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S, the cycloalkyl or the heterocycloalkyl ring being optionally substituted with one to three substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2. In another embodiment, the two R 10 Together with the atoms to which they are attached, they form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S. In another embodiment, the two R 10 Together with the atoms to which they are attached, they form a (C5-C7)cycloalkyl. 10 Together with the atoms to which they are attached, they form a (C5-C6)cycloalkyl. In yet another embodiment, two R 10 Together with the atoms to which they are attached, they form a (C6-C7)cycloalkyl. 10 Together with the atoms to which they are attached, they form a (C5)cycloalkyl. In yet another embodiment, two R 10 Together with the atoms to which they are attached, they form a (C6)cycloalkyl. 10 Together with the atoms to which they are attached they form a (C7)cycloalkyl.

[0397] In another embodiment, two R 10 Together with the atoms to which they are attached, they form a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S. In another embodiment, the two R 10 Together with the atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S. In another embodiment, the two R 10 Together with the atoms to which they are attached, they form a 6- or 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S. In another embodiment, the two R 10 Together with the atoms to which they are attached, they form a 5-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S. In another embodiment, the two R 10 Together with the atoms to which they are attached, they form a 6-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S. In another embodiment, the two R 10 Together with the atoms to which they are attached they form a 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N and S.

[0398] In another embodiment, when two R 10 When attached to the same carbon atom, they together form a (C5-C7)spirocycloalkyl or a 5- to 7-membered spiroheterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, and the spirocycloalkyl or the spiroheterocycloalkyl ring is optionally substituted with one to three substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2. In another embodiment, when two R 10 When on adjacent carbon atoms, a (C5-C7) cycloalkyl or a 5- to 7-membered heterocycloalkyl ring is formed, the heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, the cycloalkyl or the heterocycloalkyl ring being optionally substituted with one to three substituents, each of the one to three substituents being independently selected from (C1-C6) alkyl, (C1-C6) haloalkyl, halogen, -OH, CN, or -NH2. In another embodiment, two R 10 Together with the carbon atoms to which they are attached, they form a bridged (C5-C7)cycloalkyl or 5- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, the cycloalkyl or the heterocycloalkyl ring being optionally substituted with one to three substituents, each of which is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2.

[0399] In some embodiments of the above formula, each R 11 is independently (C1-C4)alkyl, (C1-C4)haloalkyl, halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, (C1-C4)haloalkyl, or halogen at each occurrence. In another embodiment, each R 11 is independently halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, (C1-C4)haloalkyl, halogen, -OH, or -NH2 at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, or halogen at each occurrence. In another embodiment, each R 11 is independently (C1-C4)haloalkyl or halogen at each occurrence. In another embodiment, each R 11 is independently halogen at each occurrence.

[0400] In another embodiment, each R 11 is independently at each occurrence (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, -OH, CN, or -NH2. Each R 11 is independently (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy, (C1-C4)haloalkoxy, or halogen at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, (C1-C4)haloalkyl, or halogen at each occurrence. In another embodiment, each R 11 is independently halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, (C1-C4)haloalkyl, halogen, -OH, or -NH2 at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, halogen, -OH, CN, or -NH2 at each occurrence. In another embodiment, each R 11 is independently (C1-C4)alkyl, or halogen at each occurrence. In another embodiment, each R 11 is independently (C1-C4)haloalkyl or halogen at each occurrence. In another embodiment, each R 11 is independently halogen at each occurrence.

[0401] In some embodiments of the above formula, R 12 is selected from (C1-C6)alkyl and (C1-C6)haloalkyl. 12 selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, and (C6-C 10 In another embodiment, R 12 is selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, and a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R 12 Selected from (C3-C7) cycloalkyl, (C6-C 10) aryl, and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R 12 is selected from a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 )aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0402] In another embodiment, R 12 is selected from (C3-C7)cycloalkyl and 4- to 7-membered heterocycloalkyl rings containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, R 12 Selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R 12 Selected from (C3-C7) cycloalkyl and (C6-C 10 In yet another embodiment, R 12 is selected from a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, and a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, R 12 is selected from (C3-C7)cycloalkyl and 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In yet another embodiment, R 12 is selected from a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, and (C6-C 10 In another embodiment, R 12 In yet another embodiment, R 12 is a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, R 12 Yes (C6-C 10 In yet another embodiment, R 12 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0403] In some embodiments of the above formula, R 13 is selected from (C1-C6)alkyl and (C1-C6)haloalkyl. 13 selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, and (C6-C 10 In another embodiment, R 13is selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, and a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R 13 Selected from (C3-C7) cycloalkyl, (C6-C 10 ) aryl, and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R 13 is selected from a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 )aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0404] In another embodiment, R 13 is selected from (C3-C7)cycloalkyl and 4- to 7-membered heterocycloalkyl rings containing 1-3 heteroatoms selected from O, N, and S. In yet another embodiment, R 13 Selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R 13 Selected from (C3-C7) cycloalkyl and (C6-C 10 In yet another embodiment, R 13 is selected from a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, and a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, R 13 is selected from (C3-C7)cycloalkyl and 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In yet another embodiment, R 13 is selected from a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, and (C6-C 10 In another embodiment, R 13 In yet another embodiment, R 13 is a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S. In another embodiment, R 13 Yes (C6-C 10 In yet another embodiment, R 13 is a 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S.

[0405] In some embodiments of the above formula, m is 0, 1, or 2. In another embodiment, m is 0 or 1. In yet another embodiment, m is 1 or 2. In another embodiment, m is 0. In yet another embodiment, m is 1. In another embodiment, m is 2.

[0406] In some embodiments of the above formula, m1 is 0, 1, or 2. In another embodiment, m1 is 0 or 1. In yet another embodiment, m1 is 1 or 2. In another embodiment, m1 is 0. In yet another embodiment, m1 is 1. In another embodiment, m1 is 2.

[0407] In some embodiments of the above formula, n1 is 0, 1, or 2. In another embodiment, n1 is 1, 2, or 3. In another embodiment, n1 is 0 or 1. In another embodiment, n1 is 1 or 2. In another embodiment, n1 is 2 or 3. In another embodiment, n1 is 0. In another embodiment, n1 is 1. In another embodiment, n1 is 2. In another embodiment, n1 is 3.

[0408] In some embodiments of the above formula, n2 is 1. In another embodiment, n2 is 2.

[0409] In some embodiments of the above formula, n3 is 1. In another embodiment, n3 is 2.

[0410] In some embodiments of the above formula, n2 is 1 and n3 is 1. In another embodiment, n2 is 2 and n3 is 1. In yet another embodiment, n2 is 1 and n3 is 2. In another embodiment, n2 is 1 or 2 and n3 is 1. In yet another embodiment, n2 is 1 or 2 and n3 is 2. In another embodiment, n2 is 1 and n3 is 1 or 2. In yet another embodiment, n2 is 2 and n3 is 1 or 2.

[0411] In some embodiments of the above formula, each s and n is independently 1, 2, or 3, wherein s + n ≤ 4. In another embodiment, each s and n is independently 1 or 2, wherein s + n ≤ 4. In another embodiment, each s and n is independently 2 or 3, wherein s + n ≤ 4. In another embodiment, s is 1 and n is 1. In another embodiment, s is 2 and n is 2. In another embodiment, s is 1 and n is 2. In another embodiment, s is 2 and n is 1. In another embodiment, s is 3 and n is 1. In another embodiment, s is 1 and n is 3.

[0412] In some embodiments of the above formula, R1 is and R2 is H or methyl.

[0413] In some embodiments of the above formula, R1 is And R5 is -OR6.

[0414] In some embodiments of the above formula, R1 is And R5 is -NR7R 7’ .

[0415] In some embodiments of the above formula, R1 is R2 is H or methyl, and R5 is -OR6.

[0416] In some embodiments of the above formula, R1 is R2 is H or methyl, and R5 is -NR7R 7’ .

[0417] In some embodiments of the above formula, R1 is And n1 is 1 or 2.

[0418] In some embodiments of the above formula, R1 is n1 is 1 or 2, and R2 is H or methyl.

[0419] In some embodiments of the above formula, R1 is n1 is 1 or 2, R2 is H or methyl, and R5 is -OR6.

[0420] In some embodiments of the above formula, R1 is n1 is 1 or 2, R2 is H or methyl, R5 is -OR6, X1 is H, and X2 is H.

[0421] In some embodiments of the above formula, R1 is n1 is 1 or 2, R2 is H or methyl, R5 is -OR6, and X1 is H.

[0422] In some embodiments of the above formula, R1 is n1 is 1 or 2, R2 is H or methyl, R5 is -OR6, and X2 is H.

[0423] In some embodiments of the above formula, R1 is n1 is 1 or 2, R2 is H or methyl, and R5 is -NR7R 7’ .

[0424] In some embodiments of the above formula, R1 is n1 is 1 or 2, R2 is H or methyl, and R5 is -NR7R 7’ , X1 is H, and X2 is H.

[0425] In some embodiments of the above formula, R1 is n1 is 1 or 2, R2 is H or methyl, and R5 is -NR7R 7’ , and X1 is H.

[0426] In some embodiments of the above formula, R1 is n1 is 1 or 2, R2 is H or methyl, and R5 is -NR7R 7’ , and X2 is H.

[0427] In some embodiments of the above formula, n1 is 1 or 2, and R2 is H or methyl.

[0428] In some embodiments of the above formula, n1 is 1 or 2, R2 is H or methyl, and R5 is -OR6.

[0429] In some embodiments of the above formula, n1 is 1 or 2, R2 is H or methyl, and R5 is -NR7R 7’ .

[0430] In some embodiments of the above formula, n1 is 1 or 2, and R5 is -OR6.

[0431] In some embodiments of the above formula, n1 is 1 or 2, and R5 is -NR7R 7’ .

[0432] In some embodiments of the above formula, R1 is n1 is 1 or 2, and m1 is 0.

[0433] In some embodiments of the above formula, R1 is n1 is 1 or 2, m1 is 0, and R5 is -OR6.

[0434] In some embodiments of the above formula, R1 is n1 is 1 or 2, m1 is 0, and R5 is -NR7R 7’ .

[0435] In some embodiments of the above formula, R2 is H or methyl, and R5 is -NR7R 7’ .

[0436] In some embodiments of the above formula, R2 is H or methyl, and R5 is -OR6.

[0437] In some embodiments of the above formula, m1 is 0, and R5 is -NR7R 7’ .

[0438] In some embodiments of the above formula, m1 is 0, and R5 is -OR6.

[0439] In some embodiments of the above formula, R1 is n1 is 1 or 2, m1 is 0, and R2 is H or methyl.

[0440] In some embodiments of the above formula, R1 is n1 is 1 or 2, m1 is 0, R2 is H or methyl, and R5 is -OR6.

[0441] In some embodiments of the above formula, R1 is n1 is 1 or 2, m1 is 0, R2 is H or methyl, and R5 is -NR7R 7’ .

[0442] In some embodiments of the above formula, R1 is And m1 is 0.

[0443] In some embodiments of the above formula, R1 is m1 is 0, and R5 is -OR6.

[0444] In some embodiments of the above formula, R1 is m1 is 0, and R5 is -NR7R 7’ .

[0445] In some embodiments of the above formula, R1 is m1 is 0, and R2 is H or methyl.

[0446] In some embodiments of the above formula, R1 is m1 is 0, R2 is H or methyl, and R5 is -OR6.

[0447] In some embodiments of the above formula, R1 is m1 is 0, R2 is H or methyl, and R5 is -NR7R 7’ .

[0448] In some embodiments of the above formula, n1 is 1 or 2, and m1 is 0.

[0449] In some embodiments of the above formula, n1 is 1 or 2, m1 is 0, and R5 is -OR6.

[0450] In some embodiments of the above formula, n1 is 1 or 2, m1 is 0, and R5 is -NR7R 7’ .

[0451] In some embodiments of the above formula, n1 is 1 or 2, m1 is 0, and R2 is H or methyl.

[0452] In some embodiments of the above formula, n1 is 1 or 2, m1 is 0, R2 is H or methyl, and R5 is -OR6.

[0453] In some embodiments of the above formula, n1 is 1 or 2, m1 is 0, R2 is H or methyl, and R5 is -NR7R 7’ .

[0454] In some embodiments of the above formula, m1 is 0, and R2 is H or methyl.

[0455] In some embodiments of the above formula, m1 is 0, R2 is H or methyl, and R5 is -OR6.

[0456] In some embodiments of the above formula, m1 is 0, R2 is H or methyl, and R5 is -NR7R 7’ .

[0457] In some embodiments of the above formula, R1 is n1 is 1 or 2, and m1 is 2.

[0458] In some embodiments of the above formula, R1 is n1 is 1 or 2, m1 is 2, and R5 is -OR6.

[0459] In some embodiments of the above formula, R1 is n1 is 1 or 2, m1 is 2, and R5 is -NR7R 7’ .

[0460] In some embodiments of the above formula, R1 is And m1 is 2.

[0461] In some embodiments of the above formula, R1 is m1 is 2, and R5 is -OR6.

[0462] In some embodiments of the above formula, R1 is m1 is 2, and R5 is -NR7R 7’ .

[0463] In some embodiments of the above formula, n1 is 1 or 2, and m1 is 2.

[0464] In some embodiments of the above formula, n1 is 1 or 2, m1 is 2, and R5 is -OR6.

[0465] In some embodiments of the above formula, n1 is 1 or 2, m1 is 2, and R5 is -NR7R 7’ .

[0466] In some embodiments of the above formula, m1 is 2, and R5 is -OR6.

[0467] In some embodiments of the above formula, m1 is 2, and R5 is -NR7R 7’ .

[0468] In some embodiments of the above formula, R1 is n is 2 and s is 1 or 2.

[0469] In some embodiments of the above formula, R1 is and R2 is H or methyl.

[0470] In some embodiments of the above formula, R1 is And R5 is -OR6.

[0471] In some embodiments of the above formula, R1 is And R5 is -NR7R 7’ .

[0472] In some embodiments of the above formula, R1 is n is 2, s is 1 or 2, and m is 0 or 1.

[0473] In some embodiments of the above formula, R1 is n is 2, s is 1 or 2, m is 0 or 1, and R2 is H or methyl.

[0474] In some embodiments of the above formula, R1 is n is 2, s is 1 or 2, m is 0 or 1, R2 is H or methyl, and R5 is -OR6.

[0475] In some embodiments of the above formula, R1 is n is 2, s is 1 or 2, m is 0 or 1, R2 is H or methyl, and R5 is -NR7R 7’ .

[0476] In some embodiments of the above formula, R1 is n is 2, s is 1 or 2, m is 0 or 1, and R5 is -OR6.

[0477] In some embodiments of the above formula, R1 is n is 2, s is 1 or 2, m is 0 or 1, and R5 is -NR7R 7’ .

[0478] In some embodiments of the above formula, R1 is And m is 0 or 1.

[0479] In some embodiments of the above formula, R1 is m is 0 or 1, and R2 is H or methyl.

[0480] In some embodiments of the above formula, R1 is m is 0 or 1, R2 is H or methyl, and R5 is -OR6.

[0481] In some embodiments of the above formula, R1 is m is 0 or 1, R2 is H or methyl, and R5 is -NR7R 7’ .

[0482] In some embodiments of the above formula, R1 is m is 0 or 1, and R5 is -OR6.

[0483] In some embodiments of the above formula, R1 is m is 0 or 1, and R5 is -NR7R 7’ .

[0484] In some embodiments of the above formula, n is 2, s is 1 or 2, and m is 0 or 1.

[0485] In some embodiments of the above formula, n is 2, s is 1 or 2, m is 0 or 1, and R2 is H or methyl.

[0486] In some embodiments of the above formula, n is 2, s is 1 or 2, m is 0 or 1, and R5 is -OR6.

[0487] In some embodiments of the above formula, n is 2, s is 1 or 2, m is 0 or 1, and R5 is -NR7R 7’ .

[0488] In some embodiments of the above formula, n is 2, s is 1 or 2, m is 0 or 1, R2 is H or methyl, and R5 is -OR6.

[0489] In some embodiments of the above formula, n is 2, s is 1 or 2, m is 0 or 1, R2 is H or methyl, and R5 is -NR7R 7’ .

[0490] In some embodiments of the above formula, n is 2, s is 1 or 2, and R2 is H or methyl.

[0491] In some embodiments of the above formula, n is 2, s is 1 or 2, and R5 is -OR6.

[0492] In some embodiments of the above formula, n is 2, s is 1 or 2, and R5 is -NR7R 7’ .

[0493] In some embodiments of the above formula, n is 2, s is 1 or 2, R2 is H or methyl, and R5 is -OR6.

[0494] In some embodiments of the above formula, n is 2, s is 1 or 2, R2 is H or methyl, and R5 is -NR7R 7’ .

[0495] In some embodiments of the above formula, m is 0 or 1, and R2 is H or methyl.

[0496] In some embodiments of the above formula, m is 0 or 1, R2 is H or methyl, and R5 is -OR6.

[0497] In some embodiments of the above formula, m is 0 or 1, R2 is H or methyl, and R5 is -NR7R 7’ .

[0498] In some embodiments of the above formula, m is 0 or 1, and R5 is -OR6.

[0499] In some embodiments of the above formula, m is 0 or 1, and R5 is -NR7R 7’ .

[0500] In some embodiments of the above formula, R1 is and R2 is H. In another embodiment, R1 is R2 is H, and m1 is 0. In another embodiment, R1 is R2 is H, m1 is O, and R5 is -OR6. In another embodiment, R1 is R2 is H, m1 is 0, R5 is -OR6, and R6 is H or (C1-C6)alkyl optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R1 is R2 is H, m1 is 0, R5 is -OR6, and R6 is H or optionally substituted by one to three (C6-C 10 In another embodiment, R1 is R2 is H, m1 is 0, R5 is -OR6, R6 is H or (C1-C6) alkyl optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, and n1 is 1 or 2. In another embodiment, R1 is R2 is H, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10 ) aryl-substituted (C1-C6) alkyl, and n1 is 1 or 2. In another embodiment, R1 is R2 is H, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10)aryl-substituted (C1-C6)alkyl, and n1 is 1. In another embodiment, R1 is R2 is H, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10 )aryl-substituted (C1-C6)alkyl, and n1 is 2.

[0501] In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , and R7 is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted with one to three R8, and R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8, and R8 is optionally substituted with one or two R 10 Substituted (C6-C 10 )aryl.

[0502] In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10 ) aryl, and n1 is 1 or 2. In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10)aryl, and n1 is 1. In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10 )aryl, and n1 is 2.

[0503] In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, and R8 is (C6-C 10 In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 ) aryl, and n1 is 1 or 2. In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 )aryl, and n1 is 1. In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 )aryl, and n1 is 2.

[0504] In some embodiments of the above formula, R1 is and R2 is methyl. In another embodiment, R1 is R2 is methyl, and m1 is 0. In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -OR6. In another embodiment, R1 is R2 is methyl, m1 is 0, R5 is -OR6, and R6 is H or (C1-C6)alkyl optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R1 is R2 is methyl, m1 is 0, R5 is -OR6, R6 is H or (C1-C6) alkyl optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, and n1 is 1 or 2. In another embodiment, R1 is R2 is methyl, m1 is 0, R5 is -OR6, R6 is H or (C1-C6) alkyl optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, and n1 is 1. In another embodiment, R1 is R2 is methyl, m1 is 0, R5 is -OR6, R6 is H or (C1-C6) alkyl optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 )aryl and a 5-membered or 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N and S, and n1 is 2.

[0505] In another embodiment, R1 is R2 is methyl, m1 is 0, R5 is -OR6, and R6 is H or optionally substituted by one to three (C6-C 10 In another embodiment, R1 is R2 is methyl, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10 ) aryl-substituted (C1-C6) alkyl, and n1 is 1 or 2. In another embodiment, R1 is R2 is methyl, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10 )aryl-substituted (C1-C6)alkyl, and n1 is 1. In another embodiment, R1 is R2 is methyl, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10)aryl-substituted (C1-C6)alkyl, and n1 is 2.

[0506] In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , and R7 is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted with one to three R8, and R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8, and R8 is optionally substituted with one or two R 10 Substituted (C6-C 10 In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10 ) aryl, and n1 is 1 or 2. In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10 )aryl, and n1 is 1. In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10 )aryl, and n1 is 2.

[0507] In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, and R8 is (C6-C 10 In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 ) aryl, and n1 is 1 or 2. In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 )aryl, and n1 is 1. In another embodiment, R1 is R2 is methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 )aryl, and n1 is 2.

[0508] In some embodiments of the above formula, R1 is R2 is H or methyl, and m1 is 0. In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -OR6. In another embodiment, R1 is R2 is H or methyl, m1 is 0, R5 is -OR6, and R6 is H or (C1-C6)alkyl optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10) aryl and a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S. In another embodiment, R1 is R2 is H or methyl, m1 is 0, R5 is -OR6, and R6 is H or optionally substituted by one to three (C6-C 10 In another embodiment, R1 is R2 is H or methyl, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10 ) aryl-substituted (C1-C6) alkyl, and n1 is 1 or 2. In another embodiment, R1 is R2 is H or methyl, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10 )aryl-substituted (C1-C6)alkyl, and n1 is 1. In another embodiment, R1 is R2 is H or methyl, m1 is 0, R5 is -OR6, R6 is H or optionally substituted by one to three (C6-C 10 )aryl-substituted (C1-C6)alkyl, and n1 is 2.

[0509] In some embodiments of the above formula, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , and R7 is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted with one to three R8, and R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted with one to three R8, and R8 is optionally substituted with one or two R 10 Substituted (C6-C 10 )aryl.

[0510] In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’, R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10 ) aryl, and n1 is 1 or 2. In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10 )aryl, and n1 is 1. In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is optionally substituted by one or two R 10 Substituted (C6-C 10 )aryl, and n1 is 2.

[0511] In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, and R8 is (C6-C 10 )aryl.

[0512] In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 ) aryl, and n1 is 1 or 2. In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 )aryl, and n1 is 1. In another embodiment, R1 is R2 is H or methyl, m1 is 0, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, R8 is (C6-C 10 )aryl, and n1 is 2.

[0513] In some embodiments of the above formula, R1 is R2 is H or methyl, m is 0, n is 1, and s is 1. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 1, s is 1, and R5 is -OR6. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 1, s is 1, R5 is -OR6, and R6 is H or optionally substituted by one to three (C6-C 10 )aryl-substituted (C1-C6)alkyl.

[0514] In some embodiments of the above formula, R1 is R2 is H or methyl, m is 0, n is 1, s is 1, and R5 is -NR7R 7’ In another embodiment, R1 is R2 is H or methyl, m is 0, n is 1, s is 1, R5 is -NR7R 7’ , and R7 is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 1, s is 1, R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted with one to three R8, and R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 1, s is 1, R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, and R8 is (C6-C 10 )aryl.

[0515] In some embodiments of the above formula, R1 is R2 is H or methyl, m is 0, n is 2, and s is 1. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1, and R5 is -OR6. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1, R5 is -OR6, and R6 is H or optionally substituted by one to three (C6-C10 )aryl-substituted (C1-C6)alkyl.

[0516] In some embodiments of the above formula, R1 is R2 is H or methyl, m is 0, n is 2, s is 1, and R5 is -NR7R 7’ In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1, and R5 is -NR7R 7’ , and R7 is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted with one to three R8, and R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, and R8 is (C6-C 10 )aryl.

[0517] In some embodiments of the above formula, R1 is R2 is H or methyl, m is 0, n is 2, and s is 2. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 2, and R5 is -OR6. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 2, R5 is -OR6, and R6 is H or optionally substituted by one to three (C6-C 10 )aryl-substituted (C1-C6)alkyl.

[0518] In some embodiments of the above formula, R1 is R2 is H or methyl, m is 0, n is 2, s is 2, and R5 is -NR7R 7’ In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 2, R5 is -NR7R 7’ , and R7 is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 2, R5 is -NR7R7’ , R7 is H or (C1-C6)alkyl optionally substituted with one to three R8, and R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 2, R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, and R8 is (C6-C 10 )aryl.

[0519] In some embodiments of the above formula, R1 is R2 is H or methyl, m is 0, n is 2, s is 1 or 2, and R5 is -OR6. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1 or 2, R5 is -OR6, and R6 is H or optionally substituted by one to three (C6-C 10 )aryl-substituted (C1-C6)alkyl.

[0520] In some embodiments of the above formula, R1 is R2 is H or methyl, m is 0, n is 2, s is 1 or 2, and R5 is -NR7R 7’ In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1 or 2, and R5 is -NR7R 7’ , and R7 is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1 or 2, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted with one to three R8, and R 7’ is H or (C1-C6)alkyl optionally substituted with one to three R8. In another embodiment, R1 is R2 is H or methyl, m is 0, n is 2, s is 1 or 2, and R5 is -NR7R 7’ , R7 is H or (C1-C6)alkyl optionally substituted by one to three R8, R 7’ is H or (C1-C6)alkyl optionally substituted by one to three R8, and R8 is (C6-C 10 )aryl.

[0521] In some embodiments of the above formula, R1 is and R2 is H or (C1-C3) alkyl. In another embodiment, R1 is R2 is H or (C1-C3) alkyl, and m1 is 0. In another embodiment, R1 is R2 is H or (C1-C3)alkyl, m1 is 0, and R5 is -NR7R 7’ In another embodiment, R1 is R2 is H or (C1-C3)alkyl, m1 is 0, and R5 is -OR6.

[0522] In some embodiments of the above formula, R1 is and R2 is H or (C1-C3) alkyl. In another embodiment, R1 is R2 is H or (C1-C3) alkyl, and m1 is 0. In another embodiment, R1 is R2 is H or (C1-C3) alkyl, m1 is 0, and R5 is -NR7R7'. In another embodiment, R1 is R2 is H or (C1-C3)alkyl, m1 is 0, and R5 is -OR6.

[0523] In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, optionally substituted with one to four R9, and n1 is 1 or 2. In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 and R 7’ Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N, and S, optionally substituted with one to four R9, and n1 is 1. In another embodiment, R1 is R2 is H, m1 is 0, and R5 is -NR7R 7’ , R7 and R 7’ Together with the nitrogen atom to which they are attached they form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N and S, optionally substituted with one to four R9, and n1 is 2.

[0524] Embodiment 1: A compound having formula (I'), wherein:

[0525] X1 and X2 are each independently H, (C1-C4) alkyl, (C1-C6) alkoxy, (C1-C4) haloalkyl,

[0526] (C1-C6)haloalkoxy, (C3-C7)cycloalkyl, halogen, CN, -OH, or -NH2;

[0527] R x is H or D;

[0528] Each R a and R b are independently H or D, or R a and R b Together with the atoms to which they are attached, they form =(O);

[0529] R1 is

[0530] R2 is H, (C1-C6)alkyl, (C1-C6)haloalkyl, or (C3-C6)cycloalkyl; or

[0531] R2 and R7 together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycloalkyl ring;

[0532] each R3, at each occurrence, is independently (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, CN, -OH, or -NH2; or

[0533] Two R3 together with the carbon atom to which they are attached form a (C3-C7)cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S; or when two R3 are on adjacent carbon atoms, together form a phenyl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N and S; or

[0534] R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, the heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, the heterocycloalkyl ring optionally substituted with one to four substituents, each of the one to four substituents being independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, and -NH2;

[0535] each R4 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, -OH, or -NH2;

[0536] R5 is -OR6 or -NR7R 7’ ;

[0537] R6 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -C(O)(C1-C6) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S;

[0538] R7 and R 7’ are each independently H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C7)cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one to four R 11 replace; or

[0539] R7 and R 7’ together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to four R9; or

[0540] R2 and R7 together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycloalkyl ring; or

[0541] R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, the heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, the heterocycloalkyl ring optionally substituted with one to four substituents, each of the one to four substituents being independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, and -NH2;

[0542] Each R8 is -C(O)OH, (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N, and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one to four R 10 replace;

[0543] Each R9, at each occurrence, is independently (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, -OH, CN, -NR 12 R 13 , or -NH2, wherein the alkoxy is optionally substituted by one to three substituents, the one to three substituents being independently selected from (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S; or

[0544] Two R9 together with the atoms to which they are attached form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N and S;

[0545] Each R 10 is independently at each occurrence (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, -OH, CN, or -NH2; or

[0546] Two R's 10 Together with the atoms to which they are attached, they form a (C4-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S, the cycloalkyl or the heterocycloalkyl ring being optionally substituted with one to four substituents each independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2;

[0547] Each R 11 is independently at each occurrence (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, -OH, CN, or -NH2;

[0548] R 12 and R 13 Each is independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S;

[0549] m and m1 are each independently 0, 1 or 2;

[0550] n1 is 0, 1, 2, or 3;

[0551] n2 and n3 are each independently 1 or 2; and

[0552] Each s and n is independently 1, 2, or 3, wherein s+n≤4;

[0553] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0554] Embodiment 2: The compound of embodiment 1, which has formula (I), wherein:

[0555] R x is H or D;

[0556] R1 is

[0557] R2 is H, (C1-C6)alkyl, (C1-C6)haloalkyl, or (C3-C6)cycloalkyl; or

[0558] R2 and R7 together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycloalkyl ring;

[0559] each R3, at each occurrence, is independently (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, CN, -OH, or -NH2; or

[0560] Two R3 together with the carbon atom to which they are attached form a (C3-C7)cycloalkyl or a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S; or when two R3 are on adjacent carbon atoms, together form a phenyl, or a 5- or 6-membered heteroaryl ring containing 1-3 heteroatoms selected from O, N and S; or

[0561] R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, the heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, the heterocycloalkyl ring optionally substituted with one to four substituents, each of the one to four substituents being independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, and -NH2;

[0562] each R4 is (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, halogen, -OH, or -NH2;

[0563] R5 is -OR6 or -NR7R 7’ ;

[0564] R6 is H, (C1-C6) alkyl, (C1-C6) haloalkyl, -C(O)(C1-C6) alkyl, (C3-C7) cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three substituents, each of which is independently selected from (C6-C 10 ) aryl and a 5-membered or 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from O, N and S;

[0565] R7 and R 7’ are each independently H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C7)cycloalkyl, a 5-membered or 6-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, N and S,

[0566] (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the alkyl is optionally substituted with one to three R8; or

[0567] R7 and R 7’ together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycloalkyl ring optionally containing 1 to 2 additional heteroatoms selected from O, N and S, which is optionally substituted with one to four R9; or

[0568] R2 and R7 together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycloalkyl ring; or

[0569] R3 and R7, together with the nitrogen and carbon atoms to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, the heterocycloalkyl ring optionally comprising 1 to 2 additional heteroatoms selected from O, N, and S, the heterocycloalkyl ring optionally substituted with one to four substituents, each of the one to four substituents being independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, and -NH2;

[0570] Each R8 is (C3-C7)cycloalkyl, a 4- to 7-membered heterocycloalkyl ring containing 1-3 heteroatoms selected from O, N and S, (C6-C 10 ) aryl, or a 5-membered or 6-membered heteroaryl containing 1-3 heteroatoms selected from O, N and S, wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted by one to four R 10 replace;

[0571] each R9, at each occurrence, is independently (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2; or

[0572] Two R9 together with the atoms to which they are attached form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N and S;

[0573] Each R 10 is independently at each occurrence (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2; or

[0574] Two R's 10 Together with the atoms to which they are attached, they form a (C5-C7)cycloalkyl or a 5- to 7-membered heterocycloalkyl ring containing 1-2 heteroatoms selected from O, N, and S, the cycloalkyl or the heterocycloalkyl ring being optionally substituted with one to four substituents each independently selected from (C1-C6)alkyl, (C1-C6)haloalkyl, halogen, -OH, CN, or -NH2;

[0575] m and m1 are each independently 0, 1, or 2;

[0576] n1 is 0, 1, 2, or 3; and

[0577] Each s and n is independently 1, 2, or 3, wherein s+n≤4;

[0578] or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.

[0579] Embodiment 3: The compound as described in embodiment 1 or 2, wherein R1 is

[0580] Embodiment 4: A compound as described in any of embodiments 1-3, wherein n1 is 1 or 2.

[0581] Embodiment 5: A compound as described in any of embodiments 1-4, wherein ml is 0.

[0582] Embodiment 6: A compound as described in any of embodiments 1-5, wherein ml is 2.

[0583] Example 7: A compound as described in Example 1, wherein R1 is

[0584] Embodiment 8. A compound as described in Embodiment 7, wherein n is 2 and s is 1 or 2.

[0585] Embodiment 9. A compound as described in Embodiment 7 or 8, wherein m is 0 or 1.

[0586] Example 10: A compound as described in Example 1 or 2, which has Formula (Ia), Formula (Ib), Formula (Ia-1) or Formula (Ib-1); or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, and tautomer thereof.

[0587] Example 11: A compound as described in Example 1 or 2, which has Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ic-1), Formula (Id-1), Formula (Ie-1), Formula (If-1), Formula (Ig-1), Formula (Ih-1), Formula (Ii-1), or Formula (Ij-1); or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, and tautomer thereof.

[0588] Example 12: A compound as described in Example 1 or 2, which has Formula (Ik), Formula (Il), Formula (Im), Formula (In), Formula (Io), Formula (Ip), Formula (Ik-1), Formula (Il-1), Formula (Im-1), Formula (In-1), Formula (Io-1), or Formula (Ip-1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, and tautomer thereof.

[0589] Embodiment 13. A compound as described in any of Embodiments 1-12, wherein R5 is -OR6.

[0590] Embodiment 14: A compound as described in any one of embodiments 1-12, wherein R5 is -NR7R 7’ .

[0591] Example 15: A compound as described in Example 1 or 2, which has Formula (Iq), Formula (Ir), Formula (Is), Formula (It), Formula (Iq-1), Formula (Ir-1), Formula (Is-1), or Formula (It-1); or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, and tautomer thereof.

[0592] Embodiment 16. A compound as described in any of embodiments 1-15, wherein R2 is H or methyl.

[0593] Embodiment 17: The compound according to embodiment 1, which is selected from:

[0594]

[0595]

[0596]

[0597]

[0598]

[0599]

[0600]

[0601]

[0602]

[0603]

[0604]

[0605]

[0606]

[0607]

[0608]

[0609]

[0610]

[0611]

[0612]

[0613]

[0614]

[0615]

[0616]

[0617]

[0618]

[0619]

[0620]

[0621]

[0622]

[0623]

[0624]

[0625]

[0626]

[0627]

[0628]

[0629]

[0630] Example 18: A pharmaceutical composition comprising a therapeutically effective amount of the compound according to any one of Examples 1-17 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

[0631] Embodiment 19: The pharmaceutical composition of embodiment 18, further comprising at least one additional pharmaceutical agent.

[0632] Example 20: The pharmaceutical composition of Example 18 or Example 19, for use in treating a disease or disorder affected by decreased IKZF2 protein levels.

[0633] Example 21: A method for degrading IKZF2, comprising administering to a patient in need thereof the compound of any one of Examples 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0634] Example 22: A method of treating a disease or disorder affected by modulation of IKZF2 protein levels, comprising administering to a patient in need thereof a compound of any one of Examples 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0635] Example 23: A method for regulating IKZF2 protein levels, comprising administering to a patient in need thereof the compound of any one of Examples 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0636] Example 24: A method of reducing cell proliferation, comprising contacting the cell with a compound of any one of Examples 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and reducing IKZF2 protein levels.

[0637] Example 25: A method for treating cancer, comprising administering to a patient in need thereof the compound of any one of Examples 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0638] Example 26: The method of Example 25, wherein the cancer is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer and soft tissue sarcoma, and the soft tissue sarcoma is selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing sarcoma.

[0639] Example 27: The method of Example 25, wherein the cancer is an immune response-deficient cancer or an immunogenic cancer.

[0640] Example 28: A method for reducing the level of IKZF2 protein in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of the compound or pharmaceutically acceptable salt of any one of Examples 1-17.

[0641] Embodiment 29: The method of any one of embodiments 21-28, wherein administration is performed orally, parenterally, subcutaneously, by injection, or by infusion.

[0642] Embodiment 30: The compound of any one of Embodiments 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder affected by decreased IKZF2 protein levels.

[0643] Example 31: Use of the compound of any one of Examples 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in the manufacture of a medicament for treating a disease or disorder affected by decreased IKZF2 protein levels.

[0644] Example 32: A compound according to any one of Examples 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease or disorder associated with decreased IKZF2 protein levels.

[0645] Embodiment 33: The compound of embodiment 32, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing sarcoma.

[0646] Example 34: Use of the compound of any one of Examples 1-17 or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof in treating a disease or disorder associated with decreased IKZF2 protein levels.

[0647] Embodiment 35: The use of embodiment 34, wherein the disease or disorder is selected from prostate cancer, breast cancer, lymphoma, leukemia, myeloma, bladder cancer, colon cancer, skin melanoma, hepatocellular carcinoma, endometrial cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, glioblastoma multiforme, glioma, thyroid cancer, parathyroid tumors, nasopharyngeal cancer, tongue cancer, pancreatic cancer, esophageal cancer, bile duct cancer, gastric cancer, and soft tissue sarcoma selected from rhabdomyosarcoma (RMS), synovial sarcoma, osteosarcoma, rhabdoid carcinoma, and Ewing sarcoma.

[0648] Example 36: A method as described in Example 25, wherein the cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).

[0649] Embodiment 37: A compound as described in embodiment 32, wherein the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).

[0650] Embodiment 38: The use as described in embodiment 34, wherein the disease or disorder is selected from non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).

[0651] In another embodiment of the present disclosure, the compounds of the present disclosure are enantiomers. In some embodiments, the compounds are (S)-enantiomers. In other embodiments, the compounds are (R)-enantiomers. In yet other embodiments, the compounds of the present disclosure can be (+) or (-) enantiomers.

[0652] It should be understood that all isomeric forms are included in the present disclosure, including mixtures thereof. If the compound contains a double bond, the substituents may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituents may have cis- or trans-configuration. All tautomeric forms are also intended to be included.

[0653] The compounds of the present disclosure and their pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, and prodrugs can exist in their tautomeric forms (e.g., as amides or imino ethers). All such tautomeric forms are considered part of the present disclosure herein.

[0654] The compounds of the present disclosure may contain asymmetric centers or chiral centers and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the present disclosure and mixtures thereof (including racemic mixtures) all constitute a part of the present disclosure. In addition, the present disclosure includes all geometric isomers and positional isomers. For example, if the compounds of the present disclosure contain double bonds or fused rings, both cis-forms and trans-forms and mixtures are included within the scope of the present disclosure. Each compound disclosed herein includes all enantiomers that meet the general structure of the compound. The compound may be in racemic or enantiomerically pure form, or any other form with respect to stereochemistry. The assay result may reflect data collected for racemic form, enantiomerically pure form or any other form with respect to stereochemistry.

[0655] Diastereomeric mixtures can be separated into their individual diastereomers based on their physicochemical differences by methods well known to those skilled in the art (such as, for example, by chromatography and / or fractional crystallization). Enantiomers can be separated by reacting the enantiomeric mixture with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chlorid), converting the enantiomeric mixture into a diastereomeric mixture, separating the diastereomers, and converting (e.g., hydrolyzing) the individual diastereomers into the corresponding pure enantiomers. In addition, some compounds of the present disclosure may be atropisomers (e.g., substituted biaryls) and are considered to be part of the present disclosure. Enantiomers can also be separated using a chiral HPLC column.

[0656] The compounds of the present disclosure may also exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure and in the chemical structures and names. In addition, for example, all keto-enol and imine-enamine forms of the compounds are included in the present disclosure.

[0657] All stereoisomers (e.g., geometric isomers, optical isomers, etc.) of the compounds of the present disclosure (including salts, solvates, esters, and prodrugs of those compounds, and salts, solvates, and esters of the prodrugs), such as those that may exist due to asymmetric carbons on different substituents (including enantiomeric forms (even asymmetric carbons may exist), rotameric forms, atropisomers, and diastereomeric forms) are included within the scope of the present disclosure, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (I') or Formula (I) contains a double bond or a fused ring, both the cis-form and the trans-form, as well as mixtures, are included within the scope of the present disclosure. In addition, for example, all keto-enol and imine-enamine forms of the compounds are included in the present disclosure). Individual stereoisomers of the compounds of the present disclosure may, for example, be substantially free of other isomers, or, for example, be present as a racemate or in admixture with all other, or other selected, stereoisomers.

[0658] The chiral centers of the compounds of the present disclosure may have the S or R configuration as defined by the IUPAC 1974 recommendations. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)-configuration. Substitutions at atoms with unsaturated double bonds may exist in cis-(Z)- or trans-(E)- form, if possible.

[0659] The use of the terms "salt," "solvate," "ester," "prodrug," and the like are intended to apply equally to enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates, or salts, solvates, esters, and prodrugs of the inventive compounds.

[0660] The compounds of the present disclosure can form salts, which are also within the scope of the present disclosure. Unless otherwise indicated, reference to a compound having a formula herein is generally understood to include reference to a salt thereof.

[0661] The compounds and intermediates can be isolated and used as the compounds themselves. Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures represented by the formulas given herein except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, chlorine, and for example, 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 18 F. 31 P. 32 P. The present disclosure includes various isotopically labeled compounds as defined herein, for example, those wherein a radioactive isotope (e.g. 3 H. 13 C. and 14 C). Such isotope-labeled compounds can be used for metabolic studies (using 14 C), reaction kinetics studies (e.g., 2 H or 3 H), detection or imaging techniques including drug or substrate tissue distribution assays (e.g., positron emission tomography (PET) or single photon emission computed tomography (SPECT)), or radiotherapy that may be used in patients. In particular, 18 F. 11 C, or labeled compounds may be particularly desirable for PET or SPECT studies.

[0662] In addition, the use of heavier isotopes, particularly deuterium (i.e. 2H or D) substitution can provide certain therapeutic advantages derived from greater metabolic stability (e.g., extended in vivo half-life, reduced dosage requirements, reduced CYP450 inhibition (competitive or time-dependent), or improved therapeutic index). For example, substitution with deuterium can modulate undesirable side effects of undeuterated compounds, such as competitive CYP450 inhibition, time-dependent CYP450 inactivation, etc. It should be understood that deuterium in this context is considered to be a substituent in the compounds of the present disclosure. The concentration of such heavier isotopes (particularly deuterium) can be defined by an isotopic enrichment factor. As used herein, the term "isotopic enrichment factor" refers to the ratio between the isotopic abundance and the natural abundance of a particular isotope. Where a substituent in a compound of the present disclosure indicates deuterium, such compound has an isotopic enrichment factor for each deuterium atom specified of at least 3500 (52.5% deuterium incorporation on each deuterium atom indicated), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

[0663] Isotopically labeled compounds of the present disclosure can generally be prepared by conventional techniques known to those skilled in the art, or by carrying out the procedures disclosed in the Schemes or Examples and Preparations described below, using an appropriate isotopically labeled reagent in place of a non-isotopically labeled reagent.

[0664] Pharmaceutically acceptable solvates according to the present disclosure include those wherein the solvent of crystallization may be isotopically substituted, for example, D2O, d6-acetone, d6-DMSO.

[0665] The present disclosure relates to compounds that are modulators of IKZF2 protein levels. In one embodiment, the compounds of the present disclosure reduce IKZF2 protein levels. In another embodiment, the compounds of the present disclosure reduce IKZF2 protein levels. In another embodiment, the compounds of the present disclosure are degraders of IKZF2.

[0666] The present disclosure relates to compounds that are modulators of IKZF2 and IKZF4 protein levels. In one embodiment, the compounds of the present disclosure reduce IKZF2 and IKZF4 protein levels. In another embodiment, the compounds of the present disclosure reduce IKZF2 and IKZF4 protein levels. In another embodiment, the compounds of the present disclosure are degraders of IKZF2.

[0667] In some embodiments, the compounds of the present disclosure are selective for other proteins. As used herein, a "selective modulator," "selective degrader," or "selective compound" means, for example, a compound of the present disclosure that effectively modulates, reduces, or lowers the level of a specific protein or degrades a specific protein to a greater extent than any other protein. For example, a "selective modulator," "selective degrader," or "selective compound" can be identified by comparing the ability of a compound to modulate, reduce, or lower the level of a specific protein or degrade a specific protein with the ability of the compound to modulate, reduce, or lower the level of other proteins or degrade other proteins. In some embodiments, the compound can be identified by measuring the EC 50 or IC 50 Identify selectivity.

[0668] In some embodiments, the compounds of the present application are selective IKZF2 modulators. As used herein, "selective IKZF2 modulators," "selective IKZF2 degraders," or "selective IKZF2 compounds" refer to compounds of the present application that, for example, effectively modulate, reduce, or lower the level of IKZF2 protein or degrade IKZF2 protein to a greater extent than any other protein, particularly any protein (transcription factor) from the Ikaros protein family (e.g., IKZF1, IKZF3, IKZF4, and IKZF5).

[0669] "Selective IKZF2 modulators," "selective IKZF2 degraders," or "selective IKZF2 compounds" can be identified, for example, by comparing the compound's ability to modulate IKZF2 protein levels with the compound's ability to modulate levels of other members of the Ikaros protein family or other proteins. For example, the ability of a substance to modulate IKZF2 protein levels as well as IKZF1, IKZF3, IKZF4, IKZF5, and other proteins can be determined. In some embodiments, the compound's EC 50 Identifying Selectivity. In some embodiments, selective IKZF2 degraders are identified by comparing the ability of a compound to degrade IKZF2 with the ability of the compound to degrade other members of the Ikaros protein family or other proteins.

[0670] In certain embodiments, the compounds of the present application are IKZF2 degraders that exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 over other proteins (e.g., IKZF1, IKZF3, IKZF4, and IKZF5). In various embodiments, the compounds of the present application exhibit up to 1000-fold selectivity for the degradation of IKZF2 over other proteins.

[0671] In certain embodiments, the compounds of the present application show at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 compared to other members of the Ikaros protein family (e.g., IKZF1, IKZF3, IKZF4, and IKZF5). In various embodiments, the compounds of the present application show up to 1000-fold selectivity for the degradation of IKZF2 compared to other members of the Ikaros protein family (e.g., IKZF1, IKZF3, IKZF4, and IKZF5).

[0672] In certain embodiments, the compounds of the present application exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 over IKZF1. In various embodiments, the compounds of the present application exhibit up to 1000-fold selectivity for the degradation of IKZF2 over IKZF1.

[0673] In certain embodiments, the compounds of the present application exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 over IKZF3. In various embodiments, the compounds of the present application exhibit up to 1000-fold selectivity for the degradation of IKZF2 over IKZF3.

[0674] In certain embodiments, the compounds of the present application exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 over IKZF4. In various embodiments, the compounds of the present application exhibit up to 1000-fold selectivity for the degradation of IKZF2 over IKZF4.

[0675] In certain embodiments, the compounds of the present application exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 over IKZF5. In various embodiments, the compounds of the present application exhibit up to 1000-fold selectivity for the degradation of IKZF2 over IKZF5.

[0676] In certain embodiments, the compounds of the present application show at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 and IKZF4 compared to other members of the Ikaros protein family (e.g., IKZF1, IKZF3, and IKZF5). In various embodiments, the compounds of the present application show up to 1000-fold selectivity for the degradation of IKZF2 and IKZF4 compared to other members of the Ikaros protein family (e.g., IKZF1, IKZF3, and IKZF5).

[0677] In certain embodiments, the compounds of the present application exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 and IKZF4 over the degradation of IKZF1. In various embodiments, the compounds of the present application exhibit up to 1000-fold selectivity for the degradation of IKZF2 and IKZF4 over the degradation of IKZF1.

[0678] In certain embodiments, the compounds of the present application exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 and IKZF4 over the degradation of IKZF3. In various embodiments, the compounds of the present application exhibit up to 1000-fold selectivity for the degradation of IKZF2 and IKZF4 over the degradation of IKZF3.

[0679] In certain embodiments, the compounds of the present application exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold selectivity for the degradation of IKZF2 and IKZF4 over the degradation of IKZF5. In various embodiments, the compounds of the present application exhibit up to 1000-fold selectivity for the degradation of IKZF2 and IKZF4 over the degradation of IKZF5.

[0680] In some embodiments, EC 50 Measuring IKZF2 degradation.

[0681] Can be obtained through EC 50 As determined under essentially similar degradation conditions, a compound with a lower EC 50 Compounds with higher EC 50 In some embodiments, substantially similar conditions include determining the degradation of protein levels in cells expressing a specific protein or any fragment thereof.

[0682] The present disclosure relates to compounds as described herein and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, as well as pharmaceutical compositions comprising one or more compounds as described herein, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof.

[0683] E. Methods for synthesizing compounds of formula (I') or formula (I)

[0684] The compounds of the present disclosure can be prepared by a variety of methods, including standard chemistry. Suitable synthetic routes are described in the schemes given below.

[0685] The compound of the present disclosure can be prepared by methods known in the field of organic synthesis, as partly described by the following synthesis scheme. In the scheme described below, it is well understood that, according to general principles or chemistry, the protecting group of a sensitive group or a reactive group is used when necessary. Protective groups are operated according to standard methods of organic synthesis (TW Greene and PGM Wuts, " Protective Groups in Organic Synthesis [protective groups in organic synthesis] ", 3rd edition, Wiley [Wiley], New York 1999). These groups are removed at a convenient stage of compound synthesis using methods obvious to those skilled in the art. The selection process and reaction conditions and their order of implementation should be consistent with the preparation of compounds with formula (I ') or formula (I).

[0686] Those skilled in the art will recognize whether there is a stereocenter in the compound of the present disclosure. Therefore, the present disclosure includes all possible stereoisomers (unless indicated in the synthesis) and includes not only racemic compounds, but also individual enantiomers and / or diastereomers. When a compound is needed as a single enantiomer or diastereomer, it can be obtained by stereospecific synthesis or by splitting the final product or any convenient intermediate. The splitting of the final product, intermediate or starting material can be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds," E.L. Eliel, S.H. Wilen, and L.N. Mander (Wiley-Interscience, 1994).

[0687] The compounds described herein can be prepared from commercially available starting materials or synthesized using known organic, inorganic and / or enzymatic methods.

[0688] Preparation of compounds

[0689] The compounds of the present disclosure can be prepared in a variety of ways well known to those skilled in the art of organic synthesis. For example, the compounds of the present disclosure can be synthesized using the methods described below, as well as synthetic methods known in the field of synthetic organic chemistry or variations thereof as understood by those skilled in the art. Preferred methods include, but are not limited to, those described below.

[0690] The compounds of the present disclosure can be synthesized by following the steps outlined in General Schemes I, II, III, IV, and V, which comprise assembling different sequences of Intermediates Ia, Ib, Ic, Id, II-b, IIIa, IV-a, IV-b, IV-c, IV-d, Va, Vb, Vc, and Vd. Starting materials are either commercially available or prepared by known procedures reported in the literature or as illustrated.

[0691] General Solution I

[0692]

[0693] where R a 、R b 、R x , R2, R3, R7, R8, X1, X2, m1, and n1 are as defined in formula (I').

[0694] The compounds of formula (I') (wherein R1 is And R 7’ is H or optionally substituted alkyl (optionally substituted with one or more R8)) is outlined in General Scheme I. a and R b When is H, coupling of Ia with 1,2-diamine Ib using a catalyst (e.g., CuI or RuPhos palladacycle), a base (e.g., cesium carbonate (Cs2CO3) or sodium tert-butoxide (t-BuONa)) in a solvent (e.g., N,N-dimethylformamide (DMF) or 1,4-dioxane), optionally at elevated temperature, yields the desired compound of formula (I') (wherein R 7’ is H). When R a and R b When taken together with the atoms to which they are attached to form =(O), coupling of Ia with 1,2-diamine Ib can be achieved using a base (e.g., i-Pr2Net) in a solvent (e.g., N-methyl-2-pyrrolidone (NMP)), optionally at elevated temperature, to afford the desired compound of formula (I') (wherein R 7’ is H). (I')(wherein R 7’ is H) with aldehyde Id to provide the desired compound of formula (I) (wherein R 7’ is an alkyl group optionally substituted with R8). Alternatively, a compound of formula (I') wherein R 7’is an alkyl group optionally substituted by R8) can be prepared by reacting (I') (wherein R 7’ (Ic) is obtained by alkylation of Ic with an alkyl halide, tosylate or mesylate.

[0695] General Solution II

[0696]

[0697] where R a 、R b 、R x , R2, R4, R7, R8, X1, X2, m, s, and n are as defined in formula (I').

[0698] The compound of formula (I') (wherein R1 is And R 7’ is H or optionally substituted alkyl (optionally substituted with one or more R8)) is outlined in General Scheme II. a and R b When is H, coupling of Ia with 1,2-diamine II-b using a catalyst (e.g., CuI or RuPhos palladacycle), a base (e.g., cesium carbonate (Cs2CO3) or sodium tert-butoxide (t-BuONa)) in a solvent (e.g., N,N-dimethylformamide (DMF) or 1,4-dioxane), optionally at elevated temperature, yields the desired compound of formula (I') (wherein R 7’ is H). When R a and R b When taken together with the atoms to which they are attached to form =(O), coupling of Ia with 1,2-diamine II-b can be achieved using a base (e.g., i-Pr2NEt) in a solvent (e.g., N-methyl-2-pyrrolidone (NMP)), optionally at elevated temperature, to afford the desired compound of formula (I') (wherein R 7’ is H). (I)(wherein R 7’ is H) with aldehyde Id to provide the desired compound of formula (I') (wherein R 7’ is an alkyl group optionally substituted with R8). Alternatively, a compound of formula (I') wherein R 7’is an alkyl group optionally substituted by R8) can be prepared by reacting (I') (wherein R 7’ (Ic) is obtained by alkylation of Ic with an alkyl halide, tosylate or mesylate.

[0699] General Scheme III

[0700]

[0701] where R a 、R b 、R x , R2, R3, R6, X1, X2, m1, and n1 are as defined in formula (I').

[0702] The compound of formula (I') (wherein R1 is And R5 is -OR6) is summarized in General Scheme III. Using a catalyst (e.g., RuPhos palladium ring complex), a base (e.g., cesium carbonate (Cs2CO3) or sodium tert-butoxide (t-BuONa)), in a solvent (e.g., N,N-dimethylformamide (DMF) or 1,4-dioxane), optionally at elevated temperature, coupling of Ia with 1,2-amino ether III-a (wherein R6 is benzyl) produces the desired compound of formula (I') (wherein R5 is -OR6 and R6 is benzyl). Compounds of formula (I') (wherein R6 is H) can be obtained by hydrogenation of (I') (wherein R6 is benzyl) in the presence of a suitable catalyst (e.g., Pd / C or PtO2), in a solvent (e.g., DMF or EtOH), and under an atmosphere of hydrogen.

[0703] General Scheme IV

[0704]

[0705] where R x , R2, R3, R7, R8, X1, X2, m1, and n1 are as defined in formula (I').

[0706] Alternatively, a compound of formula (I') wherein R1 is R a and R b is H, and R 7’(wherein R is H or optionally substituted alkyl (optionally substituted with one or more R)) can be prepared using intermediates Ib, Ic, Id, IV-a, IV-b, IV-c, and IV-d (outlined in General Scheme IV). Alkylation of IV-a with dimethylformamide (DMF) in the presence of a base (e.g., LiTMP, LDA, TMPMgCl·LiCl, etc.) in a solvent (e.g., tetrahydrofuran (THF), etc.), and optionally at low temperature, provides IV-b. Reaction of IV-b and IV-c in the presence of a reducing agent (e.g., sodium triacetoxyborohydride (NaB(OAc)3H), sodium cyanoborohydride (NaBH3CN), etc.) in a solvent (e.g., DMF, THF, etc.) provides IV-d. Coupling of IV-d with 1,2-diamine Ib using a catalyst (e.g., CuI or RuPhos palladacycle), a base (e.g., cesium carbonate (Cs2CO3) or sodium tert-butoxide (t-BuONa)) in a solvent (e.g., N,N-dimethylformamide (DMF) or 1,4-dioxane), optionally at elevated temperature, yields the desired compound of formula (I') (wherein R 7’ is H). (I')(wherein R 7’ is H) with aldehyde Id to provide the desired compound of formula (I') (wherein R 7’ is an alkyl group optionally substituted with R8). Alternatively, a compound of formula (I') wherein R 7’ is an alkyl group optionally substituted by R8) can be prepared by reacting (I') (wherein R 7’ (Ic) is obtained by alkylation of Ic with an alkyl halide, tosylate or mesylate.

[0707] General Solution V

[0708]

[0709] where R x , R2, R3, R7, R8, X1, X2, m1, and n1 are as defined in formula (I').

[0710] The compound of formula (I') (wherein R1 is R a and R b Together with the atoms to which they are attached, they form =(O), and R 7’is H or optionally substituted alkyl (optionally substituted with one or more R8) is outlined in General Scheme V. Reaction of Va with IV-c in the presence of a weak base (e.g., KOAc) in a solvent (e.g., HOAc), optionally at elevated temperature, yields intermediate Vb. Coupling of Vb with 1,2-diamine Vc (protected if necessary with an appropriate amine protecting group (e.g., Boc, Cbz, etc.) can be achieved by using a base (e.g., i-Pr2NEt) in a solvent (e.g., N-methyl-2-pyrrolidone (NMP), isopropanol (i-PrOH), optionally at elevated temperature) to afford Vd (where R 7’ is H). Alternatively, this coupling can be carried out using a catalyst (e.g., CuI or RuPhos palladacycle), a base (e.g., cesium carbonate (Cs2CO3) or sodium tert-butoxide (t-BuONa)) in a solvent (e.g., N,N-dimethylformamide (DMF) or 1,4-dioxane), optionally at elevated temperature. If the amine protecting group on Vd is a Boc group, deprotection can be achieved using a strong acid (e.g., HCl or trifluoroacetic acid (TFA)) in a solvent (e.g., tetrahydrofuran (THF), 1,4-dioxane, etc.) to provide a compound having (I') (where R 7’ is H). (I')(wherein R 7’ is H) with aldehyde Id to provide the desired compound of formula (I') (wherein R 7’ is an alkyl group optionally substituted with R8). Alternatively, a compound of formula (I') wherein R 7’ is an alkyl group optionally substituted by R8) can be obtained by alkylation of (I') (wherein R7' is H) with an alkyl halide, tosylate or mesylate Ic in the presence of a base (e.g., Et3N, i-Pr2NEt, Cs2CO3, etc.) in a solvent (e.g., MeCN, N,N-dimethylformamide (DMF), etc.), and optionally at an elevated temperature.

[0711] Mixtures of enantiomers, diastereomers and cis / trans isomers obtained by the methods described above can be separated into their individual components by chiral salt techniques, chromatography using normal phase, reverse phase or chiral columns, depending on the nature of the separation.

[0712] The compound of the present disclosure of any gained or the racemate of intermediate can be split into optical antipodes by known methods, for example, by separating its diastereomeric salt obtained with optically active acid or alkali, and releasing optically active acidic or basic compounds. Especially, therefore the compound of the present disclosure can be split into their optical antipodes using basic moieties, for example, by the fractional crystallization of the salt formed with optically active acid (for example tartaric acid, dibenzoyltartaric acid, diacetyltartaric acid, two-O, O'-toluoyltartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid). The racemic compound of the present disclosure or racemic intermediate can also be split by chiral chromatography (for example, using high pressure liquid chromatography (HPLC) of chiral adsorbent).

[0713] Any resulting mixtures of stereoisomers can be separated into the pure or substantially pure geometric or optical isomers, diastereomers, racemates on the basis of the physicochemical differences of the constituents, for example, by chromatography and / or fractional crystallization.

[0714] It is understood that in the description and formula shown above, the different groups R x , R2, R3, R4, R6, R7, R8, X1, X2, m, m1, n, n1, and s, and other variables are as defined above unless otherwise indicated. In addition, for synthetic purposes, the compounds of General Schemes I, II, III, IV, and V are merely representatives of groups selected to illustrate the general synthetic methods of compounds having Formula (I') as defined herein.

[0715] F. Methods of using compounds of formula (I') or formula (I)

[0716] Another aspect of the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating a disease or disorder in a patient associated with modulation of IKZF2 protein levels. The method comprises administering to a patient in need of treatment for a disease or disorder associated with modulation of IKZF2 protein levels an effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0717] In another aspect, the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating a disease or disorder affected by modulation of IKZF2 protein levels. The method comprises administering to a patient in need of treatment for a disease or disorder affected by modulation of IKZF2 protein levels an effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0718] In another aspect, the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating a disease or disorder affected by a decrease in IKZF2 protein levels. The method comprises administering to a patient in need of treatment for a disease or disorder affected by a decrease in IKZF2 protein levels an effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0719] Another aspect of the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating a disease or disorder affected by a reduction in IKZF2 protein levels. The method comprises administering to a patient in need of treatment for a disease or disorder affected by a reduction or reduction in IKZF2 protein levels an effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0720] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder affected by modulation of IKZF2 protein levels.

[0721] In another aspect, the present disclosure relates to the use of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder affected by a decrease or reduction in IKZF2 protein levels.

[0722] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder affected by modulation of IKZF2 protein levels.

[0723] Another aspect of the present disclosure relates to a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder affected by a decrease or reduction in IKZF2 protein levels.

[0724] In another aspect, the present disclosure relates to a method for regulating IKZF2 protein levels. The method involves administering to a patient in need thereof an effective amount of a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In some embodiments, IKZF2 protein levels are regulated by degradation of the IKZF2 protein. In other embodiments, IKZF2 protein levels are regulated by degradation of the IKZF2 protein mediated by an E3 ligase.

[0725] Another aspect of the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating a disease or disorder in a patient associated with a decrease or reduction in IKZF2 protein levels, comprising administering to a patient in need thereof an effective amount of a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound having Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0726] The present disclosure also relates to the use of an IKZF2 degrader for preparing a medicament for treating, preventing, inhibiting or eliminating an IKZF2-dependent disease or disorder, wherein the medicament comprises a compound of formula (I') or formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of formula (I') or formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0727] In another aspect, the present disclosure relates to a method for treating, preventing, inhibiting, or eliminating an IKZF2-dependent disease or disorder, wherein the medicament comprises a compound of Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0728] In another aspect, the present disclosure relates to a method for manufacturing a medicament for treating, preventing, inhibiting, or eliminating an IKZF2-dependent disease or disorder, wherein the medicament comprises a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of Formula (I') or Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0729] Another aspect of the present disclosure relates to a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease or disorder associated with regulation of IKZF2 protein levels. In some embodiments, IKZF2 levels are regulated by degradation of the IKZF2 protein. In some embodiments, IKZF2 protein levels are regulated by degradation of the IKZF2 protein mediated by an E3 ligase.

[0730] Another aspect of the present disclosure relates to a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease associated with regulation of IKZF2 protein levels. In some embodiments, IKZF2 levels are regulated by degradation of the IKZF2 protein. In some embodiments, IKZF2 protein levels are regulated by degradation of the IKZF2 protein mediated by an E3 ligase.

[0731] In another aspect, the present disclosure relates to a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease associated with regulation of IKZF2 protein levels. In some embodiments, IKZF2 protein levels are regulated by degradation of the IKZF2 protein. In some embodiments, IKZF2 protein levels are regulated by degradation of the IKZF2 protein mediated by an E3 ligase.

[0732] Another aspect of the present disclosure relates to a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a compound of formula (I') or formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease or disorder associated with a decrease in IKZF2 protein levels. In some embodiments, IKZF2 levels are decreased by degradation of the IKZF2 protein. In some embodiments,...

Claims

1. A compound selected from the group consisting of: 3-(5-(((1S,2S)-2-hydroxycyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-hydroxycyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-hydroxycyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-hydroxycyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-hydroxycyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1R,2R)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1S,2R)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1R,2S)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1S,2S)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl(2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(benzylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(benzylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(benzylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(benzylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(Benzylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(benzyloxy)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(benzyloxy)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(benzyloxy)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(benzyloxy)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(Benzyloxy)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(Benzyl(methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(Benzyl(methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(Benzyl(methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(Benzyl(methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(Benzyl(methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-aminocyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-aminocyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-aminocyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-aminocyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-aminocyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(isopropylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(isopropylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(isopropylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(isopropylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(isopropylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4aS,8aS)-octahydroquinoxalin-1(2H)-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4aR,8aS)-octahydroquinoxalin-1(2H)-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4aR,8aR)-octahydroquinoxalin-1(2H)-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4aS,8aR)-octahydroquinoxalin-1(2H)-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(octahydroquinoxalin-1(2H)-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(ethyl((1S,2S)-2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(ethyl((1S,2R)-2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(ethyl((1R,2R)-2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(5-(ethyl((1R,2S)-2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(ethyl((2-(ethylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1S,2S)-2-(methylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1S,2R)-2-(methylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1R,2R)-2-(methylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(5-(methyl((1R,2S)-2-(methylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl(2-(methylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(ethyl((1S,2S)-2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(5-(ethyl((1S,2R)-2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(5-(ethyl((1R,2S)-2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(ethyl(2-(ethylamino)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(Benzyl(methyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-((cyclohexylmethyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-((cyclohexylmethyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-((cyclohexylmethyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-((cyclohexylmethyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-((cyclohexylmethyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(((1S,2S)-2-(piperidin-1-yl)cyclopentyl)amino)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(((1S,2R)-2-(piperidin-1-yl)cyclopentyl)amino)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(((1R,2R)-2-(piperidin-1-yl)cyclopentyl)amino)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(((1R,2S)-2-(piperidin-1-yl)cyclopentyl)amino)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-((2-(piperidin-1-yl)cyclopentyl)amino)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-(isobutylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(isobutylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(isobutylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(isobutylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(isobutylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1S,6S)-6-(methylamino)cyclohex-3-en-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1S,6R)-6-(methylamino)cyclohex-3-en-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1R,6R)-6-(methylamino)cyclohex-3-en-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1R,6S)-6-(methylamino)cyclohex-3-en-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl(6-(methylamino)cyclohex-3-en-1-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 5-(((1R,2R)-2-(dimethylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-2-(dimethylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2S)-2-(dimethylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-2-(dimethylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((2-(dimethylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2S)-2-aminocyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-2-aminocyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2R)-2-aminocyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-2-aminocyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((2-aminocyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2S)-2-(ethylamino)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2R)-2-(ethylamino)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2R)-2-(ethylamino)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2S)-2-(ethylamino)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-((2-(ethylamino)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-2-(methylamino)cycloheptyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2R)-2-(methylamino)cycloheptyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2R)-2-(methylamino)cycloheptyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2S)-2-(methylamino)cycloheptyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(2-(methylamino)cycloheptyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2R)-2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2R)-2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2S)-2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,6S)-6-(methylamino)cyclohex-3-en-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,6R)-6-(methylamino)cyclohex-3-en-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,6R)-6-(methylamino)cyclohex-3-en-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,6S)-6-(methylamino)cyclohex-3-en-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(6-(methylamino)cyclohex-3-en-1-yl)amino)isoindoline-1,3-dione; 3-(5-(((1S,2S)-2-aminocyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-aminocyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-aminocyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-aminocyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-aminocyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-2-(methylamino)cyclopentyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2R)-2-(methylamino)cyclopentyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2R)-2-(methylamino)cyclopentyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2S)-2-(methylamino)cyclopentyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(2-(methylamino)cyclopentyl)amino)isoindoline-1,3-dione; 5-(((1S,2S)-2-(Benzylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-2-(Benzylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2R)-2-(Benzylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-2-(Benzylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((2-(Benzylamino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2R)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2R)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2S)-2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-2-((pyridin-3-ylmethyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2R)-2-((pyridin-3-ylmethyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2R)-2-((pyridin-3-ylmethyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2S)-2-((pyridin-3-ylmethyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(2-((pyridin-3-ylmethyl)amino)cyclohexyl)amino)isoindoline-1,3-dione; ((1S,2S)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)(methyl)amino)cyclohexyl)glycine ((1R,2S)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)(methyl)amino)cyclohexyl)glycine ((1R,2R)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)(methyl)amino)cyclohexyl)glycine ((1S,2R)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)(methyl)amino)cyclohexyl)glycine (2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)(methyl)amino)cyclohexyl)glycine 5-(((1S,2S)-2-(dimethylamino)cyclohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-2-(dimethylamino)cyclohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2R)-2-(dimethylamino)cyclohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-2-(dimethylamino)cyclohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((2-(dimethylamino)cyclohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(3-(methylamino)bicyclo [ 2.2.1]hept-5-en-2-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((2S,3S)-3-(methylamino)bicyclo[ 2.2.1]hept-5-en-2-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((2S,3R)-3-(methylamino)bicyclo[ 2.2.1]hept-5-en-2-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((2R,3R)-3-(methylamino)bicyclo[ 2.2.1]hept-5-en-2-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((2R,3S)-3-(methylamino)bicyclo[ 2.2.1]hept-5-en-2-yl)amino)isoindoline-1,3-dione; 3-(4-fluoro-5-(methyl((1S,2S)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-fluoro-5-(methyl((1S,2R)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-fluoro-5-(methyl((1R,2R)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-fluoro-5-(methyl((1R,2S)-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-fluoro-5-(methyl(2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(methyl((1S,2S)-2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(methyl((1S,2R)-2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(methyl((1R,2R)-2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(methyl((1R,2S)-2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(methyl(2-(methylamino)cyclohexyl)amino)isoindoline-1,3-dione; 3-(5-(((1S,2S)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2S)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2R)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2R)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2S)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-((2-(3-ethoxyazetidin-1-yl)cyclohexyl)(methyl)amino)isoindoline-1,3-dione; 3-(5-(((1S,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 5-(((1S,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 3-(5-(((1S,2S)-2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 5-(((1S,2S)-2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2R)-2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((2-(((3,3-difluorocyclobutyl)methyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 3-(5-(methyl((1S,2S)-2-(piperidin-1-yl)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1S,2R)-2-(piperidin-1-yl)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1R,2R)-2-(piperidin-1-yl)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl((1R,2S)-2-(piperidin-1-yl)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(methyl(2-(piperidin-1-yl)cyclopentyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-2-(piperidin-1-yl)cyclopentyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2R)-2-(piperidin-1-yl)cyclopentyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2R)-2-(piperidin-1-yl)cyclopentyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2S)-2-(piperidin-1-yl)cyclopentyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(2-(piperidin-1-yl)cyclopentyl)amino)isoindoline-1,3-dione; 5-(((1S,2S)-2-(diethylamino)cyclopentyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-2-(diethylamino)cyclopentyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2R)-2-(diethylamino)cyclopentyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-2-(diethylamino)cyclopentyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((2-(diethylamino)cyclopentyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2S)-2-(3-ethoxyazetidin-1-yl)cyclopentyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2R)-2-(3-ethoxyazetidin-1-yl)cyclopentyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2R)-2-(3-ethoxyazetidin-1-yl)cyclopentyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2S)-2-(3-ethoxyazetidin-1-yl)cyclopentyl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-((2-(3-ethoxyazetidin-1-yl)cyclopentyl)(methyl)amino)isoindoline-1,3-dione; 5-(((1S,2S)-1-amino-2,3-dihydro-1H-inden-2-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-1-amino-2,3-dihydro-1H-inden-2-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2R)-1-amino-2,3-dihydro-1H-inden-2-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-1-amino-2,3-dihydro-1H-inden-2-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((1-amino-2,3-dihydro-1H-inden-2-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2S)-1-(ethylamino)-2,3-dihydro-1H-inden-2-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2S)-1-(ethylamino)-2,3-dihydro-1H-inden-2-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2R)-1-(ethylamino)-2,3-dihydro-1H-inden-2-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2R)-1-(ethylamino)-2,3-dihydro-1H-inden-2-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-((1-(ethylamino)-2,3-dihydro-1H-inden-2-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2S)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2R)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2R)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(1-(methylamino)-2,3-dihydro-1H-inden-2-yl)amino)isoindoline-1,3-dione; 5-(((1S,2S)-2-amino-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2R)-2-amino-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2R)-2-amino-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1R,2S)-2-amino-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-((2-amino-2,3-dihydro-1H-inden-1-yl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-2-(methylamino)-2,3-dihydro-1H-inden-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2R)-2-(methylamino)-2,3-dihydro-1H-inden-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2R)-2-(methylamino)-2,3-dihydro-1H-inden-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1R,2S)-2-(methylamino)-2,3-dihydro-1H-inden-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(methyl(2-(methylamino)-2,3-dihydro-1H-inden-1-yl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2S)-2-(ethylamino)-2,3-dihydro-1H-inden-1-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1S,2R)-2-(ethylamino)-2,3-dihydro-1H-inden-1-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2R)-2-(ethylamino)-2,3-dihydro-1H-inden-1-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-(((1R,2S)-2-(ethylamino)-2,3-dihydro-1H-inden-1-yl)(methyl)amino)isoindoline-1,3-dione; 2-(2,6-dioxopiperidin-3-yl)-5-((2-(ethylamino)-2,3-dihydro-1H-inden-1-yl)(methyl)amino)isoindoline-1,3-dione; 3-(4-amino-5-(((1S,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-amino-5-(((1S,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-amino-5-(((1R,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-amino-5-(((1R,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(4-amino-5-((2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-4-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-4-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-4-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-4-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-4-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 4-amino-5-(((1S,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 4-amino-5-(((1S,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 4-amino-5-(((1R,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 4-amino-5-(((1R,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 4-amino-5-((2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; 5-(((1S,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione; 5-(((1S,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione; 5-(((1R,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione; 5-(((1R,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione; 5-((2-((4,4-difluorocyclohexyl)amino)cyclohexyl)(methyl)amino)-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione; 3-(5-(((1S,2S)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-(3-ethoxyazetidin-1-yl)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-(3-ethoxyazetidin-1-yl)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2R)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,2S)-2-((4,4-difluorocyclohexyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2-((4,4-difluorocyclohexyl)amino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; rac-trans-2-(2,6-dioxopiperidin-3-yl)-5-(octahydroquinoxalin-1(2H)-yl)isoindoline-1,3-dione; trans-3-(5-(methyl(-2-(methylamino)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione; and 2-(2,6-dioxopiperidin-3-yl)-5-(methyl((1S,2S)-2-(methylamino)cyclopentyl)amino)isoindoline-1,3-dione; or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

3. The pharmaceutical composition of claim 2, further comprising at least one additional pharmaceutical agent.

4. A pharmaceutical composition as claimed in claim 2 or claim 3 for use in treating a disease or disorder affected by a reduction in IKZF2 protein levels.

5. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for degrading IKZF2.

6. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease or disorder affected by the modulation of IKZF2 protein levels.

7. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for regulating the level of IKZF2 protein.

8. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for reducing cell proliferation or reducing the level of IKZF2 protein.

9. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer.

10. The use according to claim 9, in, The cancer is selected from non-small cell lung cancer (NSCLC), melanoma, triple negative breast cancer (TNBC), nasopharyngeal carcinoma (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, acute myeloid leukemia, and gastrointestinal stromal tumor (GIST).

11. The use according to claim 9, in, The cancer is an immune response-deficient cancer or an immunogenic cancer.

12. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for reducing the level of IKZF2 protein in a subject.

13. The use according to any one of claims 5 to 12, in, Administration is performed orally, parenterally, subcutaneously, by injection, or by infusion.

14. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or disorder affected by a decrease in IKZF2 protein levels.